Risk Assessment and Risk Management Plan

(Consultation version) for

**DIR 216**

Commercial release of cotton genetically modified for insect resistance and herbicide tolerance (Bollgard® 3 ThryvOn® cotton with XtendFlex® Technology)

Applicant: Bayer CropScience Pty Ltd

**This RARMP is open for consultation until** **9 September 2025**.

Written comments on the risks to human health and safety and the environment posed by this proposed release are invited. You may make your submission

via the consultation hub: <https://consultations.health.gov.au/ogtr/dir-216>

via mail to: The Office of the Gene Technology Regulator

 MDP 54, GPO Box 9848, Canberra ACT 2601 or

via email to: ogtr@health.gov.au.

Please note that issues regarding food safety and labelling, the use of agricultural chemicals, and marketing and trade implications do **not** fall within the scope of these evaluations as they are the responsibilities of other agencies and authorities.

Summary of the Risk Assessment and Risk Management Plan

**Consultation Version**

**for**

**Licence Application No. DIR 216**

***Introduction***

The Gene Technology Regulator (the Regulator) has received a licence application for the intentional release of a genetically modified organism (GMO) into the environment. The Regulator has prepared a draft Risk Assessment and Risk Management Plan (RARMP) for this application, which concludes that the proposed release poses negligible risks to the health and safety of people and the environment. Licence conditions have been drafted for the proposed release. The Regulator invites submissions on the RARMP, including draft licence conditions, to inform the decision on whether or not to issue a licence.

***The application***

|  |  |
| --- | --- |
| Project title  | Commercial release of cotton genetically modified for insect resistance and herbicide tolerance (Bollgard® 3 ThryvOn® with XtendFlex® Technology cotton)[[1]](#footnote-2) |
| Parent organism | Cotton (*Gossypium hirsutum L.*) |
| Introduced genes and modified traits | **4 insect resistance genes:*** *mCry51Aa2* gene from *Bacillus thuringiensis* (Bt)
* *cry1Ac* gene from Bt
* *cry2Ab* gene from Bt
* *vip3A* synthetic gene from Bt

**3 herbicide tolerance genes:*** *cp4 epsps* gene (two copies) from *Agrobacterium sp*. strain CP4 (glyphosate tolerance)
* *bar* gene from *Streptomyces hygroscopicus* (glufosinate tolerance)
* *dmo* gene from *Stenotrophomonas maltophilia* (dicamba tolerance)

**4 selectable marker genes:*** *nptII* gene from *Escherichia coli* (antibiotic resistance)
* *aph4* gene from *E. coli* (antibiotic resistance)
* *uidA* gene from *E. coli* (reporter)
* *aad* gene from *E. coli* (antibiotic resistance)
 |
| Previous releases | The proposed GM cotton has been approved for field trials in Australia under DIR 147 and DIR 203 in Australia. It has been approved for commercial cultivation in the United States of America (USA) and for food and feed use in several other countries.  |
| Proposed locations | Australia-wide |
| Principal purpose | Commercial release of the GM cotton |

***Risk assessment***

The risk assessment process considers how the genetic modification and activities conducted with the GMO might lead to harm to people or the environment. Risks are characterised in relation to both the seriousness and likelihood of harm, taking into account information in the application, relevant previous approvals, current scientific knowledge and advice received from a wide range of experts, agencies and authorities consulted on the preparation of the RARMP. Both the short- and long-term risks were considered.

Credible pathways to potential harm that were considered included exposure of people or other non-target organisms to the GM plant material, potential for persistence or dispersal of the GMOs, and transfer of the introduced genetic material to other GM or non-GM cotton plants. Potential harms associated with these pathways included adverse health effects in people or toxicity to organisms, and environmental harms due to weediness.

The risk assessment concludes that risks to the health and safety of people or the environment from the proposed dealings are negligible. No specific risk treatment measures are required to manage these negligible risks. The principal reasons for the conclusion of negligible risks are:

* the GM cotton has been produced by conventional breeding of 5 GM parental cotton lines, of which 4 have been approved for commercial release. The fifth has been approved for field trial in Australia. The risks associated with the GM parental cottons and combinations thereof, have been assessed previously as negligible and this RARMP has found no new information to change these conclusions.
* the genes and their products have been assessed as posing no increased risk of toxicity or allergenicity to humans, or toxicity to other organisms.
* the GM cotton has limited capacity to spread and persist in undisturbed environments and can be controlled using integrated weed management in agricultural and high intensity use areas.
* food made from the GM parental cotton lines has been approved by Food Standards Australia New Zealand (FSANZ) as safe for human consumption and this approval also covers food from offspring produced by conventional breeding.

***Risk management***

Risk management is used to protect the health and safety of people and to protect the environment by controlling or mitigating risk. The risk management plan evaluates and treats identified risks and considers general risk management measures. The risk management plan is given effect through licence conditions.

The risk management plan concludes that risks from the proposed dealings can be managed to protect people and the environment by imposing general conditions to ensure that there is ongoing oversight of the release.

As the level of risk is assessed as negligible, specific risk treatment is not required. However, the Regulator has drafted licence conditions regarding post-release review (PRR) to ensure that there is ongoing oversight of the release and to allow the collection of information to verify the findings of the RARMP. The draft licence, detailed in Chapter 4 of the consultation RARMP, also contains several general conditions relating to ongoing licence holder suitability, auditing and monitoring, and reporting requirements, which include an obligation to report any unintended effects.

Table of contents

[Summary of the Risk Assessment and Risk Management Plan i](#_Toc202531944)

[Table of contents iii](#_Toc202531945)

[Abbreviations v](#_Toc202531946)

[Chapter 1 Risk assessment context 1](#_Toc202531947)

[Section 1 Background 1](#_Toc202531948)

[1.1 Interface with other regulatory schemes 2](#_Toc202531949)

[Section 2 The proposed release 2](#_Toc202531950)

[Section 3 The parent organism 3](#_Toc202531951)

[Section 4 The GM parental cottons – nature and effect of genetic modification 3](#_Toc202531952)

[4.1 The genetic modifications of the GM parents and the GMO 4](#_Toc202531953)

[4.2 GM BG3 cotton 4](#_Toc202531954)

[4.3 GM XF cotton 6](#_Toc202531955)

[4.4 GM MON-88702-4 cotton 7](#_Toc202531956)

[Section 5 The GMO – nature and effect of genetic modification 10](#_Toc202531957)

[5.1 Introduction to the GMO 10](#_Toc202531958)

[5.2 Characterisation of the GMO 10](#_Toc202531959)

[5.3 Toxicity and allergenicity of the proteins encoded by the introduced genes 14](#_Toc202531960)

[5.4 Effects of the GMO on non-target invertebrates 15](#_Toc202531961)

[5.5 Experience from cultivation of the GMO 15](#_Toc202531962)

[5.6 Approvals of the GMO 16](#_Toc202531963)

[Section 6 The receiving environment 16](#_Toc202531964)

[6.1 Relevant agronomic practices 16](#_Toc202531965)

[6.2 Relevant abiotic factors 17](#_Toc202531966)

[6.3 Relevant biotic factors 17](#_Toc202531967)

[Chapter 2 Risk assessment 20](#_Toc202531968)

[Section 1 Introduction 20](#_Toc202531969)

[Section 2 Risk Identification 21](#_Toc202531970)

[2.1 Risk source 21](#_Toc202531971)

[2.2 Causal pathway 23](#_Toc202531972)

[2.3 Potential harm 24](#_Toc202531973)

[2.4 Postulated risk scenarios 24](#_Toc202531974)

[Section 3 Uncertainty 31](#_Toc202531975)

[Section 4 Risk evaluation 32](#_Toc202531976)

[Chapter 3 Risk management plan 33](#_Toc202531977)

[Section 1 Background 33](#_Toc202531978)

[Section 2 Risk treatment measures for substantive risks 33](#_Toc202531979)

[Section 3 General risk management 33](#_Toc202531980)

[3.1 Applicant suitability 33](#_Toc202531981)

[3.2 Testing methodology 34](#_Toc202531982)

[3.3 Identification of the persons or classes of persons covered by the licence 34](#_Toc202531983)

[3.4 Reporting requirements 34](#_Toc202531984)

[3.5 Monitoring for compliance 34](#_Toc202531985)

[Section 4 Post release review 34](#_Toc202531986)

[4.1 Adverse effects reporting system 35](#_Toc202531987)

[4.2 Requirement to monitor specific indicators of harm 35](#_Toc202531988)

[4.3 Review of the RARMP 35](#_Toc202531989)

[Section 5 Conclusions of the consultation RARMP 35](#_Toc202531990)

[Chapter 4 Draft licence conditions 36](#_Toc202531991)

[Section 1 Interpretations and Definitions 36](#_Toc202531992)

[Section 2 Licence conditions and obligations 36](#_Toc202531993)

[2.1 General obligations of the licence holder 36](#_Toc202531994)

[2.2 Provision of new information to the Regulator 37](#_Toc202531995)

[2.3 Obligations of persons covered by the licence 38](#_Toc202531996)

[Section 3 Reporting and documentation 38](#_Toc202531997)

[3.1 Annual Report 38](#_Toc202531998)

[ATTACHMENT A 39](#_Toc202531999)

[References 41](#_Toc202532000)

[Appendix A: Additional Data tables 44](#_Toc202532001)

[Appendix B: Summary of submissions 49](#_Toc202532002)

Abbreviations

| *aad* | *3”(9)-O-aminoglycoside adenyltransferase* gene |
| --- | --- |
| *aph4* | *hygromycin B phosphotransferase* gene |
| APVMA | Australian Pesticides and Veterinary Medicines Authority |
| *bar* | *bialaphos resistance* (*phosphinothricin N-acetyltransferase*) gene |
| BGII | Bollgard® II GM cotton |
| BG3 | Bollgard® 3 GM cotton |
| BG3 RRF | Bollgard® 3 Roundup Ready Flex® GM cotton |
| BG3 XF | Bollgard® 3 XtendFlex®GM cotton |
| *Bt* | *Bacillus thuringiensis* |
| CaMV | Cauliflower mosaic virus |
| *cp4 epsps* | *epsps* gene from *Agrobacterium sp*. strain CP4 |
| CP4 EPSPS | EPSPS protein from *Agrobacterium sp*. strain CP4 |
| CRDC | Cotton Research and Development Corporation |
| Cry | Crystal protein |
| *cry1Ac* | *cry1Ac* gene from *B. thuringiensis* |
| Cry1Ac | Cry1Ac crystal protein from *B. thuringiensis* |
| *cry2Ab* | *cry2Ab* gene from *B. thuringiensis* |
| Cry2Ab | Cry2Ab crystal protein from *B. thuringiensis* |
| DIR | Dealing involving Intentional Release |
| *dmo* | *dicamba monooxygenase* gene from *Stenotrophomons maltophilia* |
| DMO | Dicamba monooxygenase |
| DNA | Deoxyribonucleic acid |
| EPSPS | 5-enolpyruvylshikimate-3-phosphate synthase |
| FMV | Figwort mosaic virus |
| FSANZ | Food Standards Australia New Zealand (formerly ANZFA) |
| GM | Genetically Modified |
| GMO | Genetically Modified Organism |
| GUS | β-glucuronidase protein |
| ha | Hectare |
| HGT | Horizontal gene transfer |
| Hsp | Heat shock protein |
| IPM | Integrated Pest Management |
| IWM | Integrated Weed Management |
| m | metre |
| *mCry51Aa2* | modified *cry51Aa2* gene from *B. thuringiensis* |
| nptII | Neomycin phosphotransferase II |
| OGTR | Office of the Gene Technology Regulator |
| PAT | phosphinothricin N-acetyl transferase |
| RARMP | Risk Assessment and Risk Management Plan |
| TGA | Therapeutic Goods Administration |
| the Regulations | Gene Technology Regulations 2001 |
| the Regulator | Gene Technology Regulator |
| RRF | Roundup Ready Flex® GM cotton |
| Ubi3 | Ubiquitin3 |
| USA | United States of America |
| USDA-APHIS | United States Department of Agriculture Animal and Plant Health Inspection Service  |
| US EPA | United States Environmental Protection Agency |
| Vip | Vegetative insecticidal protein |
| *vip3Aa* | *vip3Aa* gene from *B. thuringiensis* |
| Vip3Aa | Vip3Aa crystal protein from *B. thuringiensis* |
| XF | XtendFlex® GM cotton |

# Risk assessment context

## Background

1. An application has been made under the *Gene Technology Act 2000* (the Act) for Dealings involving the Intentional Release (DIR) of genetically modified organisms (GMOs) into the Australian environment.
2. The Act and the Gene Technology Regulations 2001 (the Regulations), together with corresponding State and Territory legislation, comprise Australia’s national regulatory system for gene technology. Its objective is to protect the health and safety of people, and to protect the environment, by identifying risks posed by or as a result of gene technology, and by managing those risks through regulating certain dealings with GMOs.
3. Section 50 of the Act requires that the Gene Technology Regulator (the Regulator) must prepare a Risk Assessment and Risk Management Plan (RARMP) in response to an application for release of GMOs into the Australian environment. Sections 50, 50A and 51 of the Act and sections 9 and 10 of the Regulations outline the matters which the Regulator must take into account and who must be consulted when preparing the RARMP.
4. The *Risk Analysis Framework* (OGTR, 2013) explains the Regulator's approach to the preparation of RARMPs in accordance with the Act and the Regulations. The Regulator has also developed operational policies and guidelines that are relevant to DIR licences. These documents are available from the Office of the Gene Technology Regulator (OGTR) [website](https://www.ogtr.gov.au/resources).
5. Figure 1 shows the information that is considered, within the regulatory framework above, in establishing the risk assessment context. This information is specific for each application. Risks to the health and safety of people or the environment posed by the proposed release are assessed within this context. Chapter 1 provides the specific information for establishing the risk assessment context for this application.



1. **Summary of parameters used to establish the risk assessment context, within the legislative requirements, operational policies and guidelines of the OGTR and the Risk Analysis Framework**
2. Since this application is for commercial purposes, it cannot be considered as a limited and controlled release application under section 50A of the Act. Therefore, under section 50(3) of the Act, the Regulator was required to seek advice from prescribed experts, agencies and authorities on matters relevant to the preparation of the RARMP. This first round of consultation included the Gene Technology Technical Advisory Committee, State and Territory Governments, Australian Government authorities or agencies prescribed in the Regulations, all Australian local councils, and the Minister for the Environment. A summary of issues contained in submissions received is provided in Appendix B.

### Interface with other regulatory schemes

1. Gene technology legislation operates in conjunction with other regulatory schemes in Australia. The GMOs and any proposed dealings may also be subject to regulation by other Australian government agencies that regulate GMOs or GM products, including Food Standards Australia New Zealand (FSANZ), the Australian Pesticides and Veterinary Medicines Authority (APVMA), the Therapeutic Goods Administration (TGA), the Australian Industrial Chemicals Introduction Scheme (AICIS) and the Department of Agriculture, Fisheries and Forestry (DAFF). These dealings may also be subject to the operation of State legislation recognising an area as designated for the purpose of preserving the identity of GM crops, non-GM crops, or both GM crops and non-GM crops, for marketing purposes.
2. APVMA has regulatory responsibility for agricultural chemicals, including herbicides and insecticidal products, in Australia. The GM cottons proposed for release meet the definition of an agricultural chemical product under the Agricultural and Veterinary Chemicals Code Act 1994, due to their production of insecticidal substances and therefore these plants are subject to regulation by the APVMA.
3. FSANZ assesses the safety of food produced using gene technology through administration of the Australia New Zealand Food Standards Code.
4. To avoid duplication of regulatory oversight, risks that have been considered by other regulatory agencies would not be re-assessed by the Regulator.

## The proposed release

1. Bayer CropScience Pty Ltd (Bayer) proposes commercial release of a GM cotton (Bollgard® 3 ThryvOn® cotton with XtendFlex® Technology) that contains 4 insect resistance genes, 3 herbicide tolerance genes, 4 selectable marker genes (3 antibiotic resistance genes and a visual marker gene).
2. The GMO is the result of conventional crossing of MON-88702-4 (also identified as ThryvOn®), Bollgard® 3, and XtendFlex® cottons. The parental GM cotton lines are identified by OECD unique identifiers MON-88702-4 and MON-15985-7 (Bollgard® II - BGII), SYN-IR102-7 (COT102), and MON-88701-3 and MON-88913-8 (Roundup Ready Flex - RRF). The GMO is identified as MON-88702-4 x MON-15985-7 x SYN-IR102-7 x MON-88701-3 x MON-88913-8.
3. For the remainder of the document Bollgard® 3 ThryvOn® cotton with XtendFlex® Technology will be referred to as ‘the GMO’. XtendFlex® (RRF x MON-88701-3) will be referred to as XF and Bollgard® 3 (BGII x COT102) as BG3.
4. The applicant is seeking approval for the release to occur Australia-wide, subject to any moratoria imposed by the States and Territories for marketing purposes. The GM cotton could be grown in all commercial cotton growing areas, and products derived from the GM plants would enter general commerce, including use in human food and animal feed.
5. The dealings involved in the proposed intentional release are:
6. conduct experiments with the GMO
7. breed the GMO
8. propagate the GMO
9. use the GMO in the course of manufacture of a thing that is not the GMO
10. grow, raise or culture the GMO
11. import the GMO
12. transport the GMO
13. dispose of the GMO

and the possession, supply or use of the GMO for the purposes of, or in the course of, any of the above.

## The parent organism

1. The parent organism is upland cotton (*Gossypium hirsutum* L.), the most commonly cultivated cotton species worldwide. Detailed information about cotton is contained in a reference document, *The Biology of* Gossypium hirsutum *L. and* Gossypium barbadense *L. (cotton)* (OGTR, 2024), which was produced to inform the risk assessment process for licence applications involving GM cotton plants. This document is available from the Resources page on the [OGTR website](https://www.ogtr.gov.au/resources/publications/biology-gossypium-hirsutum-l-and-gossypium-barbadense-l-cotton). Baseline information from this document will be used and referred to throughout the RARMP.
2. Cotton is exotic to Australia and is grown as an agricultural crop in New South Wales (NSW) and Queensland (Qld), with recent expansion into northern Victoria (Vic), Western Australia (WA) and in the Northern Territory (NT). Cotton is grown as a source of textile and industrial fibre, cottonseed oil and linters for food use, and cottonseed meal for animal feed.
3. In establishing the risk context, details of the parent organism forms part of the baseline for a comparative risk assessment (OGTR 2013). Non-GM cotton is the standard baseline for biological comparison, although it should be noted that over 99.5 % of the Australian grown cotton is GM, expressing either insect resistance, herbicide tolerance, or both traits (OGTR, 2021).
4. Areas where cotton can be grown in Australia are mainly limited by water availability, the suitability of the soil, temperature and the length of the growing season. Cotton is grown as a dryland and/or irrigated crop, depending on the rainfall in the production area.
5. Based on 2023/2024 estimates of commercial cropping areas and production volume in Australia, cotton is ranked seventh in area of production and sixth in total production among Australian crops ([ABARES, 2024](https://www.agriculture.gov.au/abares/research-topics/agricultural-outlook/australian-crop-report/december-2024); Crop Data). In 2023/2024, the cotton production area in Australia was estimated at 474,000 hectares (ha); this area is forecast to decrease to 458,000 ha in 2024/2025, in part, due to marginal rainfall in cotton growing regions (ABARES, 2024).

## The GM parental cottons – nature and effect of genetic modification

1. The GMO is produced by conventional breeding of the following GM parental cottons:
* Insect resistant MON-88702-4 (ThryvOn®) cotton
* Insect resistant BG3 cotton (coventional crossing of BGII and COT102 cotton)
* Herbicide tolerant XF cotton (conventional crossing of MON-88701-3 and RRF cotton).
1. Both BG3 and XF cottons have been extensively evaluated in previous RARMPs for limited and controlled release and commercial release (Table 1). Therefore, this section will provide only summary information for these GM parental cotton lines.
2. Previous releases of the parental cotton lines

|  |  |  |
| --- | --- | --- |
| Cotton (Commercial name) | OECD Unique Identifier | Previous licencesa |
| ThryvOn® | MON-88702-4 | DIRs 147, 203 (L&C) |
| BG3 | MON-15985-7 (BGII) | DIRs 120, 203 (L&C)DIRs [012](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-0122002), [059](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-0592005), [066](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-0662006), [124](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-124)b, [145](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-145)c (C) |
|  | SYN-IR102-7 (COT102) | DIRs 017, 025, 034, 036, 058, 065, 073, 101, 120, 203 (L&C) DIRs [124](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-124)b, [145](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-145)c, [157](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-157) (C) |
| XF | MON-88701-3 | DIRs 120, 203 (L&C) DIR [145](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-145)c (C)  |
|  | MON-88913-8 (RRF) | DIRs 035, 203 (L&C)DIRs [059](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-0592005), [066](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-0662006), [124](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-124)b, [145](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-145)c (C) |

**a** C: Commercial release; L&C: Limited and Controlled release

b As part of BG3

c Individually and with MON-15985-7, MON88701-3, SYN-IR102-7 and MON-88913-8 in BG3 XF

1. The insect resistant GM cotton line MON-88702-4 was evaluated for limited and controlled release under DIR [147](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-147), individually and in combination with the other parental cotton lines and was also included in DIR 203. It has not been approved for commercial cultivation in Australia and has few commercial cultivation approvals worldwide. Thus, the current RARMP will focus mainly on MON-88702-4, including the *mCry51Aa2* gene, the mCry51Aa2 protein and its metabolites.

### The genetic modifications of the GM parents and the GMO

1. The introduced genetic material, source organisms and traits are summarised in Table 2.
2. Events MON-88702-4, COT102, MON-88701-3 and RRF were all produced by *Agrobacterium tumefaciens*-mediated transformation. The BGII event was produced using both *Agrobacterium tumefaciens*-mediated transformation and microprojectile bombardment (biolistics). These methods have been widely used in Australia and worldwide for introducing genes into plants. More information can be found in the document [Methods of plant genetic modification](https://www.ogtr.gov.au/resources/publications/risk-assessment-reference-methods-plant-genetic-modification) on the OGTR Risk Assessment References webpage. The parental BG3 and XF cottons were subsequently produced by conventional crossing of these lines (see paragraph 21), and the GMO by conventional crossing of MON-88702-4, BG3 and XF. Detailed assessments of the genetic modification of the parental lines are provided in the DIR licences listed in Table 1 and further discussion of the GM parental cottons is in sections 4.2 – 4.4.

### GM BG3 cotton

1. As noted, BG3 was approved for commercial release in Australia in 2014 (DIR 124). Both parental lines (BGII and COT102) were approved for commercial release in earlier licences and BG3 cotton combined with XF was approved (as BG3 XF) for commercial release in 2016 (DIR 145). See Table 1 for more information.

#### Genetic modification and introduced genes

1. BG3 contains 3 genes conferring insect resistance (*cry1Ac, cry2Ab, vip3Aa*), 4 marker genes (3 antibiotic resistance genes and a reporter gene) and regulatory elements (Table 2).
2. The RARMPs prepared for DIR 124 and DIR 145 contain extensive discussion of BG3, including the method of genetic modification, molecular stability, the introduced genes and regulatory elements and the proteins encoded by the introduced genes. These RARMPs considered the potential toxicity and allergenicity to humans, toxicity to animals (including non-target arthropods), effects on soil microorganisms and the presence of identical or similar genes and proteins in the environment. These risk assessments concluded that there was negligible risk of harm to people, other beneficial organisms or the environment from the introduced genes and their expression in the BG3 cotton.
3. The Regulator has not received reports of adverse effects on human health, animal health or the environment caused by BG3 as a crop. Literature searches did not find any information indicating adverse effects of BG3 cotton on human health and safety or the environment.

#### Other approvals of BG3

1. Regulatory systems in some countries do not require separate authorisation for environmental release of GMOs produced by conventional crossing between other already authorised GMOs. In all following discussions of international approvals, if a country with this type of system has approved the parental events, this will be noted.
2. To date BG3 cotton has been approved for direct use or processing in food in Japan and Mexico in 2014. BG3 RRF (also expresses the *cp4epsps* gene for glyphosate tolerance) was approved for direct use or processing in food in Japan (2014). Both GM parents of BG3 cotton have been approved in the United States of America (USA), Canada and China ([ISAAA GM approval](https://www.isaaa.org/gmapprovaldatabase/) and [CropLife International](http://www.biotradestatus.com/index.cfm) databases; accessed March 2025).
3. Genetic elements in the GMO and their origin

| **Gene (Source)** | **Protein produced** | **Function** | **Promoter (source)** | **Terminator (source)** | **Additional elements (source)** | **Present in** |
| --- | --- | --- | --- | --- | --- | --- |
| *mCry51Aa2**(Bacillus thuringiensis* *(Bt))* | Modified crystal protein 51Aa2 | Resistance to hemipteran & thysanopteran insects | Hsp81-2 (*Arabidopsis thaliana*) | 35S (CaMV) | E-FMV (Enhancer region of Figwort mosaic virus DNA) | MON-88702-4 (ThryvOn®) |
| *cry1Ac (Bt*) | Crystal protein 1Ac | Resistance to lepidopteran insects  | 35S (CaMV) | 7S 3’ *(Glycine max*) |  | BG3 |
| *cry2Ab (Bt)* | Crystal protein 2Ab2 | Resistance to lepidopteran insects | 35S (CaMV)  | nos (*Agrobacterium tumefaciens*) | PetHSP70 (*Petunia x hybrida*), Ctp2 (*A. thaliana*) | BG3 |
| *vip3A* (*Bt*) | Vegetative insecticidal protein 3A | Resistance to lepidopteran insects | actin2 (*A. thaliana*) | nos *(A. tumefaciens)* |  | BG3 |
| *cp4 epsps**(Agrobacterium sp.* strain CP4) | 5-enolpyruvylshikimate-3-phosphate synthase  | Tolerance to glyphosate  | P-FMV/TSF2 (Figwort mosaic virus/*A. thaliana*)P-35S/ACT8 (CaMV/*A. thaliana*) | rbcs-E9 (*Pisum sativum* – pea)rbcs-E9 (*P. sativum*) | Ctp2 (*A. thaliana*)Ctp2 (*A. thaliana*) | XF |
| *bar**(Streptomyces hygroscopicus)* | Phosphinothricin N-acetyl transferase (PAT) | Tolerance to glufosinate | 35S (CaMV) | nos *(A. tumefaciens)* | HSP70 (*P. x hybrida*) | XF |
| *dmo**(Stenotrophomonas maltophilia)* | Dicamba monooxygenase | Tolerance to dicamba | PC1SV(Peanut chlorotic streak caulimovirus) | E6 3’ (*Gossypium barbadense*) | TEV (Tobacco etch virus)Ctp2 (*A. thaliana*) | XF |
| *aad**(Escherichia coli)* | 3”(9)-O-aminoglycoside adenyltransferase  | Marker - Antibiotic resistance (streptomycin) | Tn7 (*E. coli*) |  |  | BG3 |
| *nptII**(E.coli)* | Neomycin phosphotransferase type II | Marker - Antibiotic resistance (kanamycin) | 35S (CaMV) | nos *(A. tumefaciens)* |  | BG3 |
| *uidA**(E. coli)* | beta-glucuronidase (GUS) | Selective marker (colour reaction) | 35S (CaMV) | nos *(A. tumefaciens)* |  | BG3 |
| *aph4**(E. coli)* | Hygromycin B phosphotransferase | Marker - Antibiotic resistance (hygromycin) | ubiquitin 3 (*A. thaliana*) | nos *(A. tumefaciens)* | ubi3 intron | BG3  |

1. FSANZ has approved both BGII and COT102 for human consumption (FSANZ, 2002, 2004). These approvals cover food produced from any offspring resulting from conventional breeding, including food produced from BG3 cotton.

### GM XF cotton

1. The XF cotton, individually and in combination with BG3 (BG3 XF), was approved for commercial release in Australia in 2016 under DIR 145.

#### Genetic modification and introduced genes

1. As mentioned previously, XF was produced by crossing RRF with MON-88701-3. Detailed consideration of the genetic modifications of RRF and MON-88701-3 is available in the RARMPs for DIR 124 and DIR 145 (Table 1).
2. The XF cotton contains glyphosate (*cp4 epsps*), glufosinate (*bar*) and dicamba (*dmo*) herbicide tolerance genes and regulatory elements (Table 2).
3. The RARMP prepared for DIR 145 includes extensive discussion of the method of genetic modification, molecular stability, the introduced genes and regulatory elements and the proteins encoded by the introduced genes. It considered potential toxicity/allergenicity to humans, animals (including non-target arthropods), effects on soil microorganisms, the presence of identical or similar genes and proteins in the environment for XF. The risk assessment concluded that there was negligible risk of harm to people, other beneficial organisms or the environment from the introduced genes or their expression in GM cottons.
4. The Regulator has not received reports of adverse effects on human health, animal health or the environment caused by XF cotton alone or in combination with BG3 as a crop. Literature searches did not find any information indicating adverse effects of XF cotton on human health and safety or the environment.

#### Other approvals of XF cotton

1. A number of countries have approved XF cotton for environmental release, as well as food and feed use (Table 3).
2. International approvals of XF cottona

| Country | Food - direct use or processing | Feed - direct use or processing | Cultivation - domestic or non-domestic use |
| --- | --- | --- | --- |
| Brazil |  2018 | 2018 | 2018 |
| Colombia | 2016 | 2016 |  |
| Japan |  2014 | 2014 |   |
| Mexico |  2015 |  |   |
| South Korea | 2016 | 2017 |  |
| Taiwan | 2015 |  |  |

a Source: ISAAA [GM approval database](http://www.isaaa.org/gmapprovaldatabase/); accessed February 2025

1. Both GM parents of XF cotton (RRF and MON-88701-3) have been approved in the USA, Canada and China ([ISAAA GM approval](https://www.isaaa.org/gmapprovaldatabase/) and [CropLife International](http://www.biotradestatus.com/index.cfm); accessed March 2025). Additionally, GM cotton produced by crossing events MON 88701-3 x RRF x BGII has been approved for food (including direct use or processing) in Mexico and Taiwan, and for food and feed (including direct use or processing) in Japan and South Korea (ISAAA [GM approval database](http://www.isaaa.org/gmapprovaldatabase/); accessed May 2025).
2. FSANZ approved both parental GM cotton lines of XF cotton for human consumption (FSANZ, 2005, 2013). FSANZ approval includes foods produced from cotton lines generated by conventional crossing of approved GM lines, including food produced from XF cotton.

### GM MON-88702-4 cotton

1. The GM MON-88702-4 cotton was approved by the Regulator for limited and controlled release under licence [DIR 147](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-147) in 2017 and is discussed in detail in that RARMP. It has not been approved for commercial release in Australia and will therefore be discussed in more detail in this RARMP.

#### The introduced genes, regulatory elements and encoded proteins

1. The MON-88702-4 event contains a modified *cry51Aa2* (*mCry51Aa2*) gene derived from *Bacillus thuringiensis* (Bt), a gram-positive bacterium commonly present in soil. The Bt bacterium produces a range of insecticidal proteins, including the crystal (Cry) proteins, also known as delta-endotoxins. This also includes the Cry1Ac and Cry2Ab proteins included in this application. Cry proteins are expressed by Bt during sporulation as inactive crystalline protoxins. They become activated when the crystalline inclusions are ingested and cleaved by proteases in the insect midgut. Like other Cry proteins, mCry51Aa2 protein encoded by *mCry51Aa2* gene, was shown to be produced in the bacteria as a protoxin and has the same mode of action (Jerga et al., 2016).
2. The MON-88702-4 event also contains non-coding regulatory elements that control expression of the introduced gene *mCry51Aa2*. These regulatory elements, listed in Table 4, are derived from plants, *A. tumefaciens* and from two plant viruses, namely Cauliflower mosaic virus and Figwort mosaic virus.
3. Introduced regulatory elements in MON-88702-4

| **Element** | **Function** | **Source** |
| --- | --- | --- |
| E-FMV  | *mCry51Aa2 enhancer* | Enhancer region of Figwort mosaic virus DNA |
| P-Hsp81-2  | *mCry51Aa2 promoter* | Promoter sequence of the heat shock protein 81-2 gene from *Arabidopsis thaliana*  |
| T-35S  | *mCry51Aa2 terminator* | Sequence of 3’ untranslated region of the 35S RNA of CaMV direct polyadenylation of mRNA in plants |

#### The mCry51Aa2 protein

1. In MON-88702-4 cotton, the modified *mCry51Aa2* gene expresses the mCry51Aa2 protein that provides resistance against targeted hemipteran (‘sucking bugs’, including aphids) and thysanopteran (thrips) insect pest species (Baum et al., 2012). Compared to the native sequence, the amino acid sequence of the mCry51Aa2 protein has 9 changes, namely 8 amino acid substitutions and one deletion of 3 amino acids, which results in a sequence similarity of 96.4%. These intentional modifications were made to increase its activity against target insect pests.
2. Individual Cry proteins have a narrow spectrum of insecticidal activity within a particular insect order (de Maagd et al., 2001). Activated Cry proteins bind to specific receptors on the brush border membrane of the midgut epithelium of susceptible species, leading to formation of membrane pores (Bravo et al., 2007; Yu et al., 1997). Formation of pores eventually leads to cell lysis and impairs the insect digestive process, which is thought to be responsible for insect death (OECD, 2007; Schnepf et al., 1998; Soberón et al., 2009).
3. Other organisms such as birds and mammals do not have specific receptors for Cry proteins and hence are not adversely affected (OECD, 2007; Schnepf et al., 1998). If consumed by birds and mammals, the Cry proteins would undergo degradation by proteases.
4. The applicant has provided data from studies in the USA that assessed the impact of mCry51Aa2 protein on 11 representative non-target invertebrate species using a diet bioassay. The representative species were selected based on the results of a previous activity spectrum assessment (Bachman et al., 2017)**,** and to ensure inclusion of different taxonomic groups, habitats and functions in the agroecosystem, the characteristics of the crop and the trait. The selected species include a pollinator, 8 beneficial insects and 2 decomposers from the soil biota. Test concentrations in this diet bioassay were based on the measured mCry51Aa2 protein expression in the tissue type(s) to which the species are most likely to be exposed in the environment. Insects are continuously exposed to mCry51Aa2 in their diet.
5. No toxicity was detected for 10 of the 11 representative species. However, the mCry51Aa2 had an adverse effect on insidious flower bug (*Orius insidiosus*), which is one of 4 Hemiptera species (the order of target pest) included in the diet bioassay. The mCry51Aa2 toxicity to *O. insidiosus* was also reported in the previous activity spectrum assessment (Bachman et al., 2017).
6. The applicant has conducted a comprehensive assessment of the impact of mCry51Aa2 on *Orius* spp*.* (*O. insidosus and O. majusculus*) using a tier-based system developed by the US EPA. This sequential assessment included initial screening study at high concentrations with continuous feeding (tier 1), tri-trophic feeding studies (tier 2-3) and a field study (tier 4), designed to refine risk characterisation by progressing towards more realistic field-based exposure conditions. Where an effect was observed or a tier outcome was inconclusive, higher-tier testing can be conducted under exposure conditions reflective of the field concentrations.
7. The tier 1-3 studies demonstrated effects of mCry51Aa2 on *Orius* *spp*., or had outcomes that were inconclusive. Thus, a field study (tier 4) was conducted for these species, comparing the impact of MON-88702-4 on abundance of predatory Hemiptera to that of a commercial (non-GM) control cotton. This study evaluated *O. insidiosus,* and 3 closely related Hemiptera species at 6 sites in the USA in 2018. Insect samples were collected 10 times over the course of the season at each site. In combined site analyses, no significant differences (p > 0.05) in abundance of the predatory hemipterans were observed between MON-88702-4 and the control. It should be noted that *O. insidiosus* is not recorded in the [Atlas of Living Australia](https://www.ala.org.au/) (accessed March 2025) and *Orius* spp. are not listed as beneficial predatory species in Australian cotton fields (OGTR, 2024).
8. A field study conducted in Australia (2019-2020) assessed the impact of the GMO on the abundance of non-target arthropods with BG3 XF as a control, thus focussing on the effects of mCry51Aa2 in GM cotton. The field trials were conducted at 5 locations including one site in WA (winter season) and 4 sites in eastern Australia (summer season). The study evaluated key Australian beneficial arthropods including 9 Hemiptera, 2 Coleoptera (beetles), one Araneae (spiders) and one Neuroptera (lacewings) species, including 7 species listed as beneficial predatory insects in Australian cotton fields (OGTR, 2024). The sites were designed in a randomised complete block with 4 replicates and arthropod abundance was measured using beat sheet samples and a suction sample from each plot.
9. There were 8 significant (p < 0.05) differences that showed lower abundance of 4 arthropod species in the GMO than the control. However, these differences were limited to a single location or a sampling method and were not consistent across sites or sampling methods. It was concluded that the differences were not indicative of adverse impacts of the GMO compared to the BG3 XF control and that overall, the study suggests that the mCry51Aa2 protein in the GMO does not adversely affect non-target arthropods compared to the BG3 XF control.

#### Genetic modification and molecular characterisation

1. As mentioned previously, the MON-88702-4 cotton was produced using *Agrobacterium*-mediated transformation (Chapter 1; subsection 4.1.1).
2. The applicant provided data that indicate the introduced gene was stably incorporated, with no plasmid backbone and antibiotic resistance gene expression cassette sequences in MON-88702-4. This was achieved by transforming 2 separate T-DNA gene cassettes, one expressing mCry51Aa2 protein and the other expressing aadA (antibiotic selectable marker). Subsequently, selective breeding was used to remove the *aadA* expression cassette from the MON-88702-4 cotton line. Next Generation Sequencing (NGS) confirmed the presence of a single *mCry51Aa2* gene expression cassette and the absence of plasmid backbone, *aadA* expression cassette and any unintended sequences.

####  Germination and dormancy

1. Characteristics affecting germination and dormancy have the potential to affect the persistence of seed in the environment and therefore the potential for weediness. The applicant conducted laboratory seed germination and dormancy tests in the USA, with seed collected from 3 field test sites with 4 replicates per site (Barberis, 2017), comparing MON-88702-4 cotton to non-GM cotton derived from DP393 cotton as the control line. At each site, 4 commercial non-GM cottons were used as reference lines, selected from a group of 7 commercially available non-GM cotton varieties used across all trial sites. Combined-site analysis compared MON-88702-4 to the control and to the range from reference varieties.
2. Germination was tested under 6 controlled temperature treatments: 3 constant temperatures (10°C, 20°C and 30°C), and 3 alternating temperature treatments (10°C/20°C, 10°C/30°C and 20°C/30°C). Measures included percentage of germinated seed, viable hard seed, viable firm swollen seed and dead seed. The percentage of viable hard seed can be included as a measure of dormancy and potentially as an indicator of weediness.
3. Significant differences (p < 0.05) were observed in 10 of the 25 combined site analysis of MON-88702-4 compared to the conventional control. At 20°C, 10°C/20°C, and 20°C/30°C, MON-88702-4 showed lower germinated seed compared to the control. At 10°C, 10°C/20°C, and 20°C/30°C, MON-88702-4 had higher percentage hard seed compared to the control. At 10°C, MON-88702-4 had a lower percentage viable firm-swollen seeds, while at 10°C/20°C, MON-88702-4 had a higher percentage, compared to the control. However, in all cases, the means for each measure were within the reference ranges. The report concluded that these differences are unlikely to be biologically meaningful in terms of weediness potential of MON-88702-4 compared to conventional cotton.
4. Considering these results, it is unlikely that there are changes to germination and dormancy which would increase the weediness of MON-88702-4 cotton compared to non-GM cotton.

#### Approvals of MON-88702-4 cotton and its products

##### Australian approvals of MON-88702-4 cotton

1. MON-88702-4 has been approved for field trials in Australia, alone and in combination with the other GM parental cottons (DIR 147 and DIR 203).
2. FSANZ assessed food from MON-88702-4 (A1154) cotton as being as safe for consumption as food derived from conventional cotton (FSANZ, 2018a). This assessment also includes foods derived from cotton lines generated by conventional crosses with MON-88702-4.

##### International approvals of MON-88702-4 cotton and its products

1. MON-88702-4 cotton has been approved internationally for cultivation, for food or for food and feed (including direct use and processing in each use), as summarised in Table 5.
2. International approvals of MON-88702-4 cottona

| Country | Food - direct use or processing | Feed - direct use or processing | Cultivation - domestic or non-domestic use |
| --- | --- | --- | --- |
| Canada | 2018 | 2018 |  |
| Colombia | 2020 |  |  |
| Japan | 2019 | 2018 |  |
| MalaysiaMexicoc | 2024NAd | 2024NA | 2024b |
| New Zealand | 2018 |  |  |
| Philippines | 2021e | 2021e |  |
| Singapore | 2022 | 2022 |  |
| South Korea | 2021 | 2021 |  |
| Taiwan | 2019f |  |  |
| USA | 2018 | 2018 | 2021 |

a Source: ISAAA [GM Approval Database | ISAAA.org](https://www.isaaa.org/gmapprovaldatabase/default.asp) unless otherwise stated; accessed February 2025

b for processing

c Source: [CropLife International](http://www.biotradestatus.com/index.cfm); accessed March 2025

d NA=Date not applicable

e expiring in 2026

f validity: 17 April 2019 - 17 April 2024.

## The GMO – nature and effect of genetic modification

### Introduction to the GMO

1. The GMO proposed for release is produced by conventional crossing between BG3, MON-88702-4 and XF cottons. Table 2 lists all of the genetic elements present in the GM parental cottons used to produce the GMO and these have been discussed in Sections 4.2 – 4.4.
2. The GM plants are phenotypically similar to non-GM cotton. They will be limited by the same abiotic factors as non-GM cotton, sexually compatible with the same plants and their products used identically to non-GM cotton. The difference between the GMO and non-GM cotton is that the GMO is tolerant to glyphosate, glufosinate and dicamba herbicides and resistant to lepidopteran, hemipteran and thysanopteran insect pests of cotton. No additional marker genes are introduced in the GMO, only those that were present in BG3 or BG3 XF.
3. Agricultural management of the GMO differs from non-GM cotton with respect to insect pest management and in the application of herbicides to control weeds in the crop. Any GMO volunteers in subsequent crops would need to be controlled by mechanical means or use of herbicides other than those to which the crop is tolerant.
4. The RARMP for DIR 147 identified additional information that may be required to assess an application for a large scale or commercial release of the GMO, or to justify a reduction in containment conditions. This included:
* Molecular, biochemical and phenotypic characterisation of the GM cotton MON-88702-4 including potential for increased toxicity, allergenicity and weediness.
* Potential toxicity to an increased range of insects of the combination of the insecticidal proteins in the GM cotton and the potential for increased weediness.
1. The applicant has provided the additional information for MON-88702-4 alone, and for the GMO (discussed below).

### Characterisation of the GMO

1. The applicant has provided data from both Australian and USA field trials for the GMO. Field trials in Australia provided protein expression data and phenotypic data. The USA field trials included data for protein expression, cottonseed composition and phenotypic measures (see Section 5.2.3).

#### Molecular Stability

1. NGS was used to confirm the presence and intactness of each of the insert genes in the GMO. The DNA sequencing data obtained from the GMO was analysed by comparing to the previously determined sequences for each of the GM parental lines. Results of this analysis confirmed that the GMO contains a single complete copy of DNA inserts of each of the parental GM cotton lines.

#### Protein expression

##### Field Trials - USA

1. In the USA field trials, concentrations of expressed proteins from the introduced genes in the GMO and GM parental lines were measured in leaves, roots and seeds samples (Table 6).
2. Protein expression for the GMO and GM parental cotton lines in US field trials

| **Protein** | **Linea** | **Leafb,c (OSL1)****(μg/g dw)** | **Leaf (OSL4)****(μg/g dw)** | **Root** **(μg/g dw)** | **Seed** **(μg/g dw)** | **Pollen****(μg/g dw)** |
| --- | --- | --- | --- | --- | --- | --- |
| mCry51Aa2 | GMO | 1200 ± 420 | 1100 ± 430  | 210 ± 39  | 170 ± 34  | 5.1 ± 1.9  |
|  |  | 580 - 1900 | 560 - 1700 | 150 - 290 | 120 - 270 | 3.8 – 8.3 |
|  | MON-88702-4 | 1500 ± 350  | 1300 ± 450  | 170 ± 30  | 140 ± 23  | 3.9 ± 1.7  |
|  |  | 870 - 1900 | 740 - 2200 | 130 - 230 | 97 - 190 | 2.7 – 7.0 |
| Cry1Ac | GMO | 51 ± 19  | 33 ± 21  | 1.5 ± 1  | 8.2 ± 1.8  | 0.41 ± 0.092  |
|  |  | 15 - 90 | 11 - 85 | 0.57 – 5.2 | 6.4 - 12 | 0.33 – 0.56 |
|  | BGII | 47 ± 15  | 21 ± 9.9  | 0.83 ± 0.34  | 9.3 ± 0.82  | 0.40 ± 0.069  |
|  |  | 12 - 69 | 9.7 - 42 | 0.4 – 1.7 | 8 - 11 | 0.29 – 0.46 |
| Cry2Ab | GMO | 880 ± 560  | 460 ± 160  | 150 ± 32  | 340 ± 49  | 0.56 ± 0.26  |
|  |  | 310 - 2100 | 290 - 940 | 100 - 190 | 240 - 410 | 0.33 – 0.96 |
|  | BGII | 710 ± 340  | 330 ± 85  | 130 ± 27  | 340 ± 64  | 0.54 ± 0.080  |
|  |  | 260 - 1600 | 230 - 530 | 94 - 190 | 260 - 500 | 0.46 – 0.65 |
| Vip 3Aa19 | GMO | 66 ± 22  | 31 ± 9  | <LOQd (NAe)  | <LOQ (NA)  | <LOQ (NA)  |
|  |  | 43 - 110 | 20 - 48 | NA - NA | NA - NA | NA - NA |
|  | COT102 | 120 ± 38  | 38 ± 14  | <LOQ (NA)  | <LOQ (NA)  | <LOQ (NA)  |
|  |  | 54 - 210 | 20 - 66 | NA - NA | NA - NA | NA - NA |
| DMO | GMO | 360 ± 140  | 150 ± 60  | 25 ± 7.8  | 51 ± 22  | <LOQ (NA)  |
|  |  | 160 - 700 | 76 - 330 | 13 - 46 | 17 - 97 | NA - NA |
|  | MON-88701-3 | 320 ± 110  | 140 ± 65  | 24 ± 7  | 29 ± 11  | <LOQ (NA)  |
|  |  | 180 - 610 | 69 - 290 | 12 - 35 | 10 - 54 | NA - NA |
| PAT | GMO | 11 ± 5.1  | 5.7 ± 2.1  | 2.9 ± 0.92  | 14 ± 3.8  | <LOQ (NA)  |
|  |  | 4.2 - 19 | 3 - 11 | 1.9 - 6.0 | 5.0 - 19 | NA - NA |
|  | MON-88701-3 | 8.5 ± 3.5  | 4.7 ± 1.6  | 2.6 ± 0.91  | 10 ± 3.6  | <LOQ (NA)  |
|  |  | 3.7 - 18 | 2.1 - 7.3 | 0.91 - 4.6 | 0.54 - 16 | NA - NA |
| CP4 EPSPS | GMO | 3800 ± 1100  | 1700 ± 690  | 260 ± 70  | 370 ± 100  | 5.0 ± 0.14  |
|  |  | 1500 - 5600 | 830 - 3300 | 130 - 400 | 160 - 540 | 4.8 – 5.1 |
|  | RRF | 2400 ± 860  | 1000 ± 380  | 240 ± 79  | 280 ± 61  | 4.3 ± 0.60  |
|  |  | 830 - 3800 | 420 - 1900 | 130 - 410 | 170 - 390 | 3.4 – 4.9 |

a For each protein, expression in the test line (the GMO) was compared to the appropriate GM parental cotton, listed in the table

b Leaf – OSL1 and OSL4, collected at 2-4 node stage and cutout stages, respectively; root and pollen collected at peak bloom stage; seed collected at maturity

c Data are shown as the mean ± standard deviation, followed by the range of values recorded across all samples

d LOQ=limit of quantitation (lowest value of concentration that can be quantified with acceptable precision and accuracy)

e NA=not applicable

1. In general, the mean concentrations of all expressed proteins are higher in all tissues tested in the GMO than in the comparable GM parental line. The exceptions are mCry51Aa2 and Vip3Aa19 (lower than parental line) in leaf tissues, Cry1Ac (lower than parental line) in seed tissue and Cry2Ab (same as parental line) in seed tissue. In addition, the protein concentrations of Vip3Aa19 in root, seed and pollen tissues, and DMO and PAT in pollen tissues were below the limit of quantitation (LOQ).
2. Although there are differences in protein expression between the GMO and parental lines, the means for all proteins in the GMO are within the ranges observed for the parental lines. The exception is CP4 EPSPS in pollen, for which the mean for the GMO is slightly above the range observed for the parental cotton.

##### Field Trials - Australia

1. Protein expression data for the GMO was collected from Australian field trials between 2018 and 2020, as summarised in Tables A1 and A2, Appendix A. In 2018-2019, samples were obtained from a single site in WA (winter 2018) and from 4 sites across NSW and Qld (summer 2018-19). In 2019-2020, samples were obtained from one site in WA (winter 2019) and 4 sites across NSW and Qld (summer 2019-20). Data were analysed separately for the WA site, while NSW and Qld site data were combined in each season. In each year, each site had 4 plots in a randomised complete block design. Protein expression levels were determined in bolls (Boll-1 and Boll-2), seeds, leaves (over season leaf (OSL), OSL1 – OSL4), pollen, and squares (Square 1-4).
2. For the insect resistance proteins, across all seasons, highest expression was measured for Cry1Ac in OSL1 and Square 1; Cry2Ab in Square 1 and seed; mCry51Aa2 in square samples (all) and for Vip3Aa19 in OSL1 (all leaf samples high) and Square 1 samples.
3. For herbicide tolerance proteins, highest expression was measured for CP4 EPSPS in leaf samples, mainly OSL1 and 2, across all seasons; for DMO in leaf (2018, 2018-19) or square samples (2019, 2019-20) and for PAT in seed and/or leaf samples across all seasons.
4. The most consistent expression pattern was observed for mCry51Aa2, with highest expression in square samples, but also high expression in leaf samples across all seasons. Additionally, pollen expression was lowest for all proteins, across all seasons.
5. Comparing between seasons, expression of Cry and Vip proteins was lower in the 2018-19 samples than for 2018, 2019 or 2019-20 samples and mCry51Aa2 expression was higher in 2019 samples than all others. For herbicide tolerance proteins, expression was generally highest in 2019 samples, with 2019-20 also high for CP4 EPSPS and DMO proteins.

#### Phenotypic characterisation of the GM cottons

##### Australian phenotypic characterisation of the GMO

1. Data for phenotypic analysis of the GMO were generated from 2018-2019 and 2019-2020 field trials in Australia. Details of the treatments in the Australian trials are as follows:
* Test: the GMO
* Control: BG3 XF (BGII x COT102 x MON-88701-3 x RRF) in a similar background line
* Each season included data from one WA site and 2 sites each in Qld and NSW
* Due to lower germination rate identified, at some sites the test lines were planted at higher rates of seeds per metre
* No chemical sprays were applied for insect control
* All other crop managements were carried out according to the commercial agronomic practices for cotton farming, including irrigation and water management, cultivation and bed preparation, weed control and plant nutrition.
1. Measures assessed were:
* Stand counts - early (21 days after planting - DAP), final (7 days prior to harvest)
* Plant vigour rating
* Plant height (every 21 days from 21 DAP)
* Number of nodes (every 21 days from 21 DAP)
* Nodes above white flower (NAWF) – 3 samples, taken weekly from 7 days after flowering (DAF)
* Cotton seed weight per plot and as kg/ha
* Lint yield per plot and kg lint/ha
* Fibre quality measures - length, uniformity, short fibre index, strength, elongation and micronaire
* Seed measures - seed index (g/100 seeds), seed number per 50 bolls on acid-delinted seed (boll sample collected 4 days prior to harvest).
1. Both combined site data (5 sites) and individual site data were analysed for 2018-2019 and 2019-2020 sites. There were few significant differences between test and control plants in either season or for individual site data (Table A3, Appendix A). Differences were:
* Plant stand counts (plants/m) were lower for test plants at one site in 2018-2019 due to susceptibility of the test cultivar to the fungal disease Verticillium wilt, but no significant difference (p < 0.05) was apparent for combined site comparisons
* Plant stand counts (plants/m) were higher for test plants at one site in 2019-2020, corresponding with a higher planting rate, but no significant difference was apparent for combined site comparisons
* Yield (kg lint/ha) was significantly lower for test plants than control plants at 2 sites in 2019-2020, but no significant difference was apparent for combined site comparisons.
1. The applicant suggested that the differences, including lower stand count and lower yield at individual sites, may have been influenced by the lower disease tolerance (e.g. to Verticillium wilt) in the test plant genetics. However, there were not consistent differences observed between the test and control plants, and their similarity in terms of growth rate and habit indicates that there was no difference in the overall agronomic performance or the phenotype of the test cotton plants compared to the control plants.

##### United States phenotypic characterisation of the GMO

1. The applicant has provided phenotypic and environmental interactions measures for 2016 season in the USA.
2. These studies compared the GMO to the control (non-GM line DP393) and commercial non-GM reference lines. Four reference lines were planted at each site, chosen from a group of 14 possible commercial lines used across all sites. Eight sites were set up as a randomised block design, with 4 replicates per site.
3. The GMO was compared to the control in a combined-site analysis for 8 phenotypic characteristics: early stand count, days to flowering, final stand count, plant height, total bolls, first position fruit retention, seed cotton yield, and seed weight.
4. The GMO was also compared to the control in a combined-site analysis for environmental interaction assessments (Table 7).
5. Environmental measures collected for US field trials of the GMO

| Measure class | Measure a |
| --- | --- |
| Abiotic stressors  | drought, flooding, hail injury, heat, nutrient deficiency, soil compaction, sandstorm, wet soil and wind |
| Disease stressors b | blights, rots, rusts, leaf spots and wilts |
| Arthropod stressors  | 9 non-lepidopteran arthropods |

a abiotic, disease and arthropod measures were by observation

b thirteen disease stressors assessed

1. Data were analysed from individual sites, as well as combined data across 8 sites. For some parameters, there were significant differences (p < 0.05) observed at individual sites, but not for combined site analyses. Likewise, a significant difference found for combined site data may not mean that each site showed a significant difference when analysed individually.
2. In the combined site analysis significant differences between the GMO and the control were observed in 2 phenotypic characteristics for the GMO: higher first position fruit retention, which showed significant differences at 3 individual sites, and lower seed weight, which showed significant differences at 6 sites (Table 8).
3. US phenotypic characterisation of the GMO

| Characteristic (units) | Mean (SE) | Mean (SE) | Reference Rangec |
| --- | --- | --- | --- |
|  | GMOa | Control a,b |  |
| Early Stand Count (plants/2 rows) | 177.8 (5.11) | 178.5 (4.94) | 148.5 - 244.6 |
| Days to floweringd | 57.1 (0.82) | 57.4 (0.98) | 50.6 - 64.1 |
| Final Stand Count (plants/2 rows) | 170.7 (5.23) | 166.1 (5.15) | 144.4 - 230.4 |
| Plant height (cm) | 94.7 (4.34) | 94.8 (4.57) | 80.0 - 166.0 |
| Total bolls (bolls/plant) | 10.0 (0.50) | 9.8 (0.57) | 3.7 - 11.8 |
| First position fruit retention (%) | 51.6 (3.60) \* | 46.0 (3.16) | 10.4 - 61.0 |
| Yield (kg/ha) | 3486.2 (221.82) | 3526.5 (210.91) | 1142.5 - 4460.5 |
| Seed weight (g) | 7.3 (0.10) \* | 8.2 (0.15) | 6.4 - 10.2 |

\*Indicates a statistically significant difference between test and the conventional control (α=0.05) using ANOVA.

a N = 32 for test/control means. SE= standard error.

b Control is non-GM commercial cotton line

c Minimum and maximum mean values among 14 references, where each mean was combined over all the sites at which the reference was planted.

d Days after planting

1. In addition to this, 4 individual sites showed significant differences between the GMO and the control for phenotypic characteristics for, including higher days to first flower (one site), higher total bolls (2 sites) and lower yield (one site), but these differences were not seen for the combined site analysis.
2. For combined site data, test and control means for all phenotypic measures were within the range for reference material across all sites. This indicates that although there were some statistically significant differences in these parameters, there were no biologically meaningful differences.
3. There were no differences observed between GMO and the control for any of the assessed abiotic, disease or arthropod stressors.

#### Compositional analysis

1. Seed collected from the GMO grown at field trial sites in the USA was analysed for proximates (protein, total fat, and ash), amino acids (18), fatty acids (7 components), carbohydrates by calculation, fibre (acid detergent fibre (ADF), neutral detergent fibre (NDF) and total detergent fibre (TDF)), minerals (calcium and phosphorus), vitamin E and anti-nutrients (gossypol and cyclopropenoid fatty acids), as well as moisture content (Table A4, Appendix A).
2. Of the 40 measures, 26 showed statistically significant (p < 0.05) differences between the GMO and non-GM control line (DP393). However, the means for all 26 measures were within the ranges available from the International Life Sciences Institute (ISLI) [Crop Composition Database](https://www.cropcomposition.org/query/index.html) (accessed February 2025) and within ranges cited in literature, as provided by the applicant.
3. In summary, although there were differences in cottonseed composition between the GMO and conventional cotton, the mean values for all measures were within the range of expected variation between lines and locations.
4. FSANZ has assessed each of the GM parental cotton lines and determined that the cotton lines are compositionally equivalent to conventional cotton and that food derived from these lines is considered to be as safe for human consumption as food derived from conventional cotton cultivars. FSANZ approval includes foods produced from cotton lines generated by conventional crossing of approved GM lines, therefore food derived from the GMO is included in these approvals.

### Toxicity and allergenicity of the proteins encoded by the introduced genes

#### Introduced herbicide tolerance and selectable marker proteins

1. The GMO contains glyphosate (*cp4 epsps*), glufosinate (*bar*) and dicamba (*dmo*) herbicide tolerance genes from XF and selectable marker genes from BG3. These introduced genetic materials, source organisms and traits are summarised in Table 2.
2. Data relating to the potential for causing toxic or allergic reactions of the introduced CP4 EPSPS, PAT, DMO and selectable marker proteins as well as their metabolic products to humans or other organisms have been detailed intheir respective RARMPs listed in Table 1, most recently in DIR 124 and DIR 145. These assessments concluded that the proteins pose negligible risk to human or other organisms. Additional information about the marker genes is available in the [*Marker genes in GM plants*](https://www.ogtr.gov.au/resources/publications/risk-assessment-reference-marker-genes-gm-plants) reference, available on the OGTR website.

#### Introduced insect resistance proteins

1. The introduced Vip3Aa19 and Cry proteins for insect resistance are derived from Bt, which is naturally found in the environment including in soil, on plant surfaces and on animals. Microbial biopesticide formulations of Bt have been used commercially for several decades (OECD, 2007). Extensive toxicity testing of the Bt biopesticides that contain numerous Cry proteins has not provided any evidence for adverse effects on human or animal health (Koch et al., 2015; McClintock et al., 1995).
2. The potential for the introduced Vip3Aa19, Cry1Ac and Cry2Ab proteins to cause toxic or allergic reactions in humans or other organisms has been assessed previously (DIR 101 and 124), with the conclusion that these proteins pose negligible risk to humans or other organisms.
3. The applicant has not supplied data related to the toxicity or allergenicity of the mCry51Aa2 protein. However, Health Canada recently assessed toxicology and allergenicity studies of mCry51Aa2 supplied by Monsanto Canada Inc. The full assessment can be found in the [Health Canada website](https://www.canada.ca/en/health-canada/services/food-nutrition/genetically-modified-foods-other-novel-foods/approved-products/cotton-event-mon-88702/document.html#a7). The following is the summary of this assessment.
4. The mCry51Aa2 toxicity studies on CD-1 mice found no adverse effects at high doses (5000 mg/kg body weight). *In silico* analysis showed no relevant similarity to known toxins, and *in vitro* tests indicated the mCry51Aa2 protein was rapidly digested in the gastrointestinal tract.
5. Heat stability tests demonstrated that the mCry51Aa2 protein was inactivated during cotton oil processing, meaning consumers would not be exposed to active protein. Additionally, cotton seed products including refined oil and cellulose contain negligible amounts of protein, thus dietary exposure to mCry51Aa2 is minimal.
6. Allergenicity assessment, including sequence comparisons and digestibility studies, showed no evidence of the mCry51Aa2 matching known allergens or being available to provoke allergic reactions.
7. Overall, cottonseed oil and linters derived from MON-88702-4 cotton are not expected to have higher toxicity or allergenicity than conventional cotton.

### Effects of the GMO on non-target invertebrates

1. No adverse effects of BG3 and XF on non-target invertebrates were identified in the RARMPs for DIR 124 and DIR 145. As previously discussed earlier in Section 4.4.2 of this Chapter, the GMO does not adversely affect non-target arthropods.
2. Synergistic, additive and antagonistic interactions between the Cry1Ac and Cry2Ab proteins were reviewed in previous RARMPs (DIR 059/2005, DIR 066/2006, DIR 124 and DIR 145), with the conclusion that Cry1Ac and Cry2Ab acted independently without any consistent evidence of any of these effects. In addition, a study examining interactions between Cry1Ac and Vip proteins in their effects on Lepidoptera species found no evidence of any interactions between Cry1Ac and Vip3Aa (Lemes et al., 2014).
3. However, recent studies reported that some combinations of these proteins showed synergistic effects against Lepidoptera pests of cotton (Liu et al., 2024). For example, Cry1Ac and Cry2Ab interacted synergistically against cotton bollworm *(Helicoverpa armigera)* and Egyptian bollworm *(Earias insulana)*, and the combination of Cry2Ab and Vip3Aa19 proteins showed synergistic effects on fall armyworm *(Spodoptera frugiperda)* larvae (Liu et al., 2024).
4. The applicant has provided data from diet incorporation bioassays that evaluated the potential for interaction between mCry51Aa2 and Cry1Ac and Cry2Ab, or Vip3Aa using 2 cotton pests. Toxicity to cotton bollworm (*Helicoverpa zea*), targeted by the Cry1Ac, Cry2Ab and Vip3Aa19 proteins, was evaluated using tissue from BGII (Cry1Ac, Cry2Ab), COT102 (Vip3Aa19) and the GMO (mCry51Aa2, Cry1Ac, Cry2Ab and Vip3Aa19) with a non-GM control. The results from this comparison demonstrated that the activity of Cry1Ac, Cry2Ab and Vip3Aa19 against this target species was not altered in the GMO, i.e. the presence of mCry51Aa2 did not affect the activity of these toxins in the GMO.
5. Toxicity to the Western tarnished plant bug (*Lygus Hesperus*) targeted by the mCry51Aa2 protein was evaluated using tissue from MON-88702-4 (mCry51Aa2) and the GMO (mCry51Aa2, Cry1Ac, Cry2Ab and Vip3Aa19), with a non-GM control. This comparison showed that the activity of mCry51Aa2 on the target organism was not altered in the GMO, i.e. the presence of the Cry1Ac, Cry2Ab and Vip3Aa19 did not affect the activity of mCry51Aa2 in the GMO.
6. Overall, these results suggest that the BG3 proteins and mCry51Aa2 protein have no synergistic or antagonistic effect on toxicity to cotton bollworm and Western tarnished plant bug.

### Experience from cultivation of the GMO

1. Field data from trials conducted with the GMO in Australia and the USA have been discussed in earlier this section (Sections 5.2.2-5.2.4). The results indicated that the GMO did not show increased weediness potential, and its composition was substantially equivalent to that of conventional cotton.
2. The GMO has been approved for field trials in Australia under DIR 147, and has been cultivated on over 172,800 ha (2021-2023) commercially in the USA (data supplied by applicant). The applicant states that no adverse consequences have been recorded from the fields trials or commercial release.

### Approvals of the GMO

1. As mentioned previously, FSANZ has approved use of oil and linters from each of the parental cottons and these approvals include material from lines generated by conventional crossing of the parents, hence the GMO is automatically approved.
2. The BG3 has been registered by the APVMA for use as an insecticidal substance. The applicant will seek APVMA approval for the cultivation of MON-88702-4 for use as an insecticidal substance, prior to commercial release of the GMO in Australia. The applicant has APVMA registrations for the use of glyphosate-, glufosinate- and dicamba-containing herbicides on herbicide tolerant cottons including RRF and MON-88701-3 (information supplied by the applicant).
3. The parental GM lines for the GMO, including MON-88702-4, have received non-regulated status from United States Department of Agriculture Animal and Plant Health Inspection Service (USDA-APHIS) in the USA (USDA-APHIS, 2002, 2004, 2005, 2012, 2021). Also, the parental GM lines have been considered safe for human consumption and approved for environmental release in Canada ([Health Canada](https://www.canada.ca/en/health-canada.html) & [CFIA](https://inspection.canada.ca/en)).
4. The GMO has been approved for food (including direct use or processing ) in Colombia and Taiwan, and for food and feed (including direct use and processing) in South Korea (ISAAA [GM approval database](http://www.isaaa.org/gmapprovaldatabase/); accessed February 2025).
5. Approvals for the GMO and its parental GM lines (BG3, XF and MON-88702-4) have been provided in earlier sections of Chapter (Section 4.2-4.4). .

## The receiving environment

1. The receiving environment forms part of the context in which the risks associated with dealings involving the GMO is assessed. Relevant information about the receiving environment includes abiotic and biotic interactions of the crop with the environment where the release would occur, agronomic practices for the crop, the presence of plants that are sexually compatible with the GMO, and background presence of the gene(s) used in the genetic modification (OGTR, 2013).
2. The applicant has proposed to release the GMO in all commercial cotton growing areas, Australia-wide. Therefore, for this licence application, it is considered that the receiving environment is all of Australia but in particular, agricultural areas that are suitable to cultivate cotton. Commercial cotton production occurs mainly in NSW, and Qld, but it is also grown in Vic, WA and the NT. The actual locations, number of sites and area of land used in the proposed release would depend on factors such as field conditions, grower demand and seed availability.
3. The cultivation practices, and abiotic and biotic factors for cotton are discussed in detail in *The Biology of Gossypium hirsutum L. and Gossypium barbadense L. (cotton)* (OGTR, 2024). The following summary is based on this document.

### Relevant agronomic practices

1. It is anticipated that the agronomic practices for cultivation of the GMO will not differ significantly from industry best practices used in Australia, where over 99% of commercial cotton grown is GM and is likely have one or more traits found in the GMO. All cotton plants would be grown following standard cotton agricultural management practices and would receive applications of water and fertilisers, similar to current commercially grown non-GM and GM cotton crops; and herbicide applications similar to current commercially grown GM cotton crops.
2. The control of cotton volunteers is usually achieved by mechanical means such as cultivation, or use of a range of herbicides, preferably as part of Integrated Weed Management (IWM) practices. Seven mode of action (MoA) groups of herbicides, including glufosinate, are currently registered for cotton volunteer control in Australia. Control of volunteer cotton by herbicides is most effective on seedling cotton and only one herbicide (fluroxypyr) is registered for control of large (15- to 30 node) volunteer cotton (CRDC, 2024). Currently, dicamba and glyphosate are not registered for use in volunteer cotton control in Australia (CRDC, 2024). For further information, refer to the [Public Chemical Registration Information System](https://portal.apvma.gov.au/pubcris/) (PubCRIS) on the APVMA website.
3. The use of Integrated Pest Management (IPM) is preferred to control insect pests. This involves using a range of tactics throughout the season to manage pest and beneficial insect populations in and around farms. Use of insecticides is only one part of this system and use of IPM is important to slow the development of insecticide resistance (CottonInfo, 2016; CRDC, 2024).

### Relevant abiotic factors

1. The abiotic factors relevant to the growth and distribution of commercial cotton in Australia are water availability (through rainfall or irrigation), soil suitability and, most importantly, temperature. Cotton seedlings may be killed by frost, growth and development of cotton plants below 12°C is minimal, and a long, hot growing season is crucial for achieving good yields.

### Relevant biotic factors

#### Presence of sexually compatible plants in the receiving environment

1. Commercial cotton grown in Australia is either *G. hirsutum* or *G. barbadense*, of which over 99% is *G. hirsutum*. The GMO proposed in this RARMP is capable of crossing with both *G. hirsutum* and *G. barbadense*.
2. In the natural environment for successful hybridisation to occur parent plants must occur in close proximity, flower at the same time, have pollen from one plant deposited on the stigma of the other, fertilisation must occur, and progeny must survive to sexual maturity. Additionally, for hybrids to persist in the environment, any progeny seed would have to be viable. Cotton is largely self-pollinating and no self-incompatibility mechanisms exist. Where cross-pollination does occur, it is likely facilitated by honeybees. Cotton does not reproduce by asexual mechanisms, although root cuttings can be propagated under laboratory conditions (OGTR, 2024).
3. Cotton (*G. hirsutum*) is not recorded in the Australian government's Weeds of National Significance list on the [Weeds Australia website](https://weeds.org.au/) (accessed February 2025), or the Noxious Weed List for Australian States and Territories (Invasive Plants and Animals Committee, 2015). Most reports of *G. hirsutum* volunteers or naturalised populations are from tropical regions of Australia, and cotton-growing areas throughout Qld and NSW ([Atlas of Living Australia](https://www.ala.org.au/) accessed June 2025). Persistence of feral populations is limited, as *G. hirsutum* has negligible ability to invade non-disturbed habitats and any such populations are not routinely subjected to control measures such as the use of herbicide and cultivation (OGTR, 2024). Records of feral cotton presence do not indicate a marked change in the number of records or the pattern of occurrence ([Australia’s Virtual Herbarium](http://avh.chah.org.au/) accessed March 2025) since the previous comprehensive review in the RARMP for DIR 124 (OGTR 2014). If gene transfer from the GM cottons to feral cotton were to occur, the presence of herbicide tolerance genes in those feral cottons would not be expected to provide a selective advantage in the absence of herbicide application. The presence of insect resistance genes is unlikely to provide a selective advantage in the absence of high pest insect pressure.
4. Populations of cotton volunteers can be found on cotton farms, by roadsides where cotton seed is transported, or in areas where cotton seed is used as livestock feed (Addison et al., 2007; Eastick and Hearnden, 2006). Volunteer seedlings that emerge over winter are likely to be killed by frosts, while dry winters may promote volunteer survival and emergence in warmer months, with spring rains and irrigation promoting volunteer growth and development.
5. As well as the parental GM cottons (Table 1), a number of other insect resistant and/or herbicide tolerant GM cotton lines have been approved for commercial release in Australia (Table 9). These form part of the risk context for this DIR licence application.
6. Australian approvals for the commercial release of other insect resistant and or herbicide tolerant GM cotton linesa.

| **GM cotton** | **Genes** | **DIR licence number** | **Comment** |
| --- | --- | --- | --- |
| Liberty Link®  | *bar* | 062/2005 | Glufosinate herbicide tolerance |
| Widestrike™ | *cry1Ac* (synthetic)*cry1F* (synthetic)*pat* | 091 | Insect resistance and glufosinate herbicide tolerance |
| GlyTol®  | *2mepsps* | 143 | Glyphosate herbicide tolerance |
| GlyTol TwinLink Plus® | *2mepsps**bar**cry 1Ab**cry 2Ae* *vip3Aa19* | 143 | Glyphosate and glufosinate herbicide tolerance and 3 insect resistance  |

aFor the licences relating to the parental lines of the GMO, see Table 1 (Section 4.1)

1. To date, the Regulator has not received any reports of adverse effects caused by these authorised releases, although it should be noted that not all of these have been planted on a commercial scale.

#### Presence of related native plants in the receiving environment

1. There are 17 native species of *Gossypium* in Australia, 12 of which are found in the relatively small coastal area in northern WA. Of the remaining species, *G. sturtianum* is the most widely distributed and is scattered across the sub-tropical to warm temperate arid zones of Australia, in Qld, NSW, SA and WA. *G. australe* has a broad east coast – west coast distribution, but its indigenous range extends from southern areas of the NT to Katherine. *G. bickii* occurs largely within central NT, while *G. nelsonii* is distributed in a band from central NT to central Qld.
2. The likelihood that cultivated *G. hirsutum* could hybridise successfully with native Australian Gossypium species is low, due to genetic incompatibility. While hybrids between *G. hirsutum* and *G. sturtianum* have been produced under field conditions, the hybrids were sterile, effectively eliminating any potential for introgression of *G. hirsutum* genes into *G. sturtianum* populations (Brown et al., 1997; Brubaker et al., 1999).

#### Presence of other biotic factors

1. The major insect pests of cotton are lepidopteran species. In Australia, the most damaging lepidopteran pests are cotton bollworm (*Helicoverpa armigera*) and native budworm (*Helicoverpa punctigera*). However, beet armyworm (*Spodoptera exigua*), cluster caterpillar (*Spodoptera litura*) and pink bollworm (*Pectinophora gossyipiella*) can also affect cotton production (OGTR, 2024). These lepidopteran pests are now managed through the widespread adoption of GM cotton varieties with Bt toxin genes that specifically target these insect pests.
2. Many cotton growing areas across Australia also have important non-lepidopteran insect pests. These include cotton aphids (*Aphis gossypii*), green mirids (*Creontiades dilutus*), brown mirids (*C. pacificus*), two-spotted spider mites (*Tetranychus urticae*), silverleaf whitefly *(Bemisia tabaci*), thrips (*Thrips tabaci, Frankliniella schultzei* and *F. occidentalis*), green vegetable bugs (*Nezara viridula*), solenopsis mealybugs (*Phenacoccus solenopsis*) and Reniform nematode (*Rotylenchulus reniformis*) (CRDC and CottonInfo, 2017).
3. Australian cotton is affected by a number of soil-borne and foliar fungal diseases, along with oomycete, bacterial and viral diseases. Fungal pathogens cause the major diseases Verticillium wilt (*Verticillium dahliae*) and Fusarium wilt (*Fusarium oxysporum* f. sp. *vasinfectum*). Common seedling diseases of cotton are black root rot (*Thielaviopsis basicola*) and damping off (caused by *Rhizoctonia solani*, *Pythium* spp. and *Phytophthora* spp.). Leaves may be affected by Alternaria leaf spot (*Alternaria* spp.) and cotton bunchy top virus spread by aphids. Boll rots are caused by different pathogens, including fungi, bacteria and oomycetes (CRDC and CottonInfo, 2017).
4. Cotton is susceptible to competition from weeds. Problematic weeds range from large plants such as Noogoora burr (*Xanthium occidentale*), Bathurst burr (*Xanthium spinosum*), thornapples (*Datura* spp.) and sesbania (*Sesbania canabina*), to vines such as cowvine and bellvine (*Ipomoea* spp.), yellow vine or spine-less caltrop (*Tribulus* spp.), to grasses such as nut grass (*Cyperus rotundus*) (CRDC, 2013). Some weed species are alternate hosts for diseases of cotton, e.g. many weeds are hosts for *V. dahliae* (CRDC and CottonInfo, 2017). These weed species have not been recorded globally as resistant to glyphosate, glufosinate or dicamba (Heap, 2025).
5. In Australia, at least 20 glyphosate-resistant and one dicamba-resistant weed species have been reported, but no glufosinate-resistant weed species have been recorded (Heap, 2025). To date, at least 11 and 5 weed species globally are reported to have resistance to dicamba and glufosinate, respectively (Heap, 2025).

#### Presence of the introduced or similar genes and encoded proteins in the receiving environment

1. The introduced genes for insect resistance and herbicide tolerance in the GMO are derived from common soil-borne microorganisms. The genetic regulatory sequences that have been used in the development of GMOs, are derived from plants, plant viruses and a common soil bacterium. All of these source organisms are present in Australia with the exception of Figwort mosaic virus (FMV) ([Atlas of Living Australia](https://www.ala.org.au/) accessed May 2025). However, FMV-derived regulatory elements are commonly used as promoters in the development of GM plants. Hence, the introduced or similar genes and regulatory sequences in the GMO are also present in the Australian environment (Table 2). The introduced selective marker genes are derived from *E. coli*, which is widespread in the environment. Thus, humans and other organisms would commonly encounter these genes and their encoded proteins (Table 2).

# Risk assessment

## Introduction

1. The risk assessment identifies and characterises risks to the health and safety of people or to the environment from dealings with GMOs, posed by or as the result of gene technology (Figure 2). Risks are identified within the established risk assessment context (Chapter 1), taking into account current scientific and technical knowledge. A consideration of uncertainty, in particular knowledge gaps, occurs throughout the risk assessment process.



1. **The risk assessment process**
2. The Regulator uses a number of techniques to identify risks, including checklists, brainstorming, previous agency experience, reported international experience and consultation (OGTR, 2013).Risk identification first considers a wide range of circumstances in which the GMO, or the introduced genetic material, could come into contact with people or the environment. This leads to postulating causal pathways that may give rise to harm for people or the environment from dealings with a GMO. These are called risk scenarios.
3. Risk scenarios are screened to identify substantive risks, which are risk scenarios that are considered to have some reasonable chance of causing harm. Risk scenarios that could not plausibly occur, or do not lead to harm in the short and long term, do not advance in the risk assessment process (Figure 2), i.e. the risk is considered no greater than negligible.
4. Risk scenarios identified as substantive risks are further characterised in terms of the potential seriousness of harm (Consequence assessment) and the likelihood of harm (Likelihood assessment). The consequence and likelihood assessments are combined to estimate the level of risk and determine whether risk treatment measures are required. The potential for interactions between risks is also considered.
5. A weed risk assessment approach is used to identify traits that may contribute to risks from GM plants, as this approach addresses the full range of potential adverse outcomes associated with plants. In particular, novel traits that may increase the potential of the GMO to spread and persist in the environment or increase the level of potential harm compared with the parental plant(s) are considered in postulating risk scenarios (Keese et al., 2014). Risk scenarios postulated in previous RARMPs prepared for licence applications for the same or similar GMOs are also considered.

## Risk Identification

1. Postulated risk scenarios are comprised of three components (Figure 3):
2. The source of potential harm (risk source),
3. A plausible causal linkage to potential harm (causal pathway), and
4. Potential harm to an object of value (people or the environment).

**source of**

**potential harm**

(a novel GM trait)

**plausible causal linkage**

**potential harm to**

 **an object of value**

(people/environment)

1. **Components of a risk scenario**
2. When postulating relevant risk scenarios, the risk context is taken into account, including the following factors detailed in Chapter 1:
* the proposed dealings,
* any proposed limits including the extent and scale of the proposed dealings,
* any proposed controls to limit the spread and persistence of the GMO, and
* the characteristics of the parent organism(s).

### Risk source

1. The source of potential harms can be intended novel GM traits associated with one or more introduced genetic elements, or unintended effects/traits arising from the use of gene technology.
2. As discussed in Chapter 1, the GMO has been modified by the introduction of 3 genes for herbicide tolerance and 4 genes for insect resistance. It also contains 4 marker genes, including 3 antibiotic resistance genes and one reporter gene.

***The introduced genes for herbicide tolerance***

1. The *cp4 epsps* and *bar* genes from the RRF parental cotton confer tolerance to the glyphosate and glufosinate herbicides, respectively. The *dmo* gene from MON-88701-3 parental cotton confers tolerance to dicamba herbicide. These genes and their encoded proteins have been evaluated in a number of commercial cotton licence RARMPs (Table 1) and were assessed as posing negligible risk to human or animal health and the environment by the Regulator. Furthermore, they have been assessed and approved by other regulatory agencies in Australia and overseas (see Chapter 1, Section 4.3).
2. The RARMP for DIR 145 considered these 3 herbicide tolerance genes in combination with respect to potential for weediness. No substantive risk was identified, as glyphosate, glufosinate and dicamba are not used commonly to control volunteer cotton or other weeds. No new information was found to change this conclusion (see Chapter 1, Section 4.3.1) and there are no additional herbicide tolerance genes in the GMO. Therefore, these genes will not be considered further as potential sources of risk for this application.

***The introduced genes for insect resistance***

1. The *cry1Ac*, *cry2Ab* and *vip3Aa* genes, which confer resistance to lepidopteran insects, along with their encoded proteins, have been assessed, individually and in combination, in a number of commercial cotton licence RARMPs (Table 1, Chapter 1). The RARMP for DIR 124 also considered the potential for interaction (e.g. synergistic or antagonistic) between these proteins that may lead to increased harm. These previous RARMPs concluded that these genes and their proteins pose negligible risk to human health or the environment. There are no credible reports of adverse effects on human health or the environment since those RARMPs were published. In addition, FSANZ has approved the use of material derived from GM cottons containing the *cry1Ac*, *cry2Ab* and/or *vip3Aa* genes and their proteins. Therefore, these 3 genes will not be individually considered further as potential sources of risk for this application.
2. The *mCry51Aa2* gene, which encodes the mCry51Aa2 protein and confers resistance to hemipteran and thysanopteran insect pests, has not been assessed previously for commercial release in Australia. This introduced gene is considered further as a potential source of risk. Additionally, the potential for interaction (e.g. synergistic or antagonistic) between mCry51Aa2 protein and Cry1Ac, Cry2Ab and Vip3Aa proteins will be considered and whether any such interaction may lead to increased harm. Interactions with other insect resistance genes from sexually compatible plants will also be considered.

***Selectable marker and reporter genes***

1. The GMO also contains 3 selectable marker genes that confer antibiotic resistance (*nptII*, *aph4* and *aad*) and a reporter gene (*uidA*). These 3 marker genes all originated from the BG3 parental line. These genes and their products have been extensively characterised and have been assessed by the Regulator as posing negligible risk to human health or to the environment, and by other regulatory agencies in Australia and overseas. Further information about these genes can be found in the document *Marker genes in GM plants* available from the [Risk Assessment References page](https://www.ogtr.gov.au/resources/publications/risk-assessment-reference-marker-genes-gm-plants) on the OGTR website. As these genes have not been found to pose a substantive risk to either people or the environment, they will not be further considered as potential sources of harm.

***The regulatory sequences***

1. The introduced genes are controlled by introduced regulatory sequences. These are derived from plants, bacteria and plant viruses (see Chapter 1, Table 2). Regulatory sequences are naturally present in plants and the introduced elements are expected to operate in similar ways to endogenous elements. The regulatory sequences are DNA that is not expressed as a protein and dietary DNA has no toxicity (Society of Toxicology 2003). As discussed in Chapter 1 and in previous RARMPs, these sequences have been widely used in other GMOs, including the parental GM lines that are grown commercially, without reports of adverse effects. Hence, risks from these regulatory sequences will not be further assessed for this application.

***Unintended effects***

1. The genetic modifications have the potential to cause unintended effects in several ways, including altered expression of endogenous genes due to random insertion of introduced DNA in the genome, increased metabolic burden due to expression of the proteins encoded by the introduced genes, novel traits arising out of interactions with non-target proteins and secondary effects arising from altered substrate or product levels in biochemical pathways. However, the range of unintended effects produced by genetic modification is not likely to be greater than that from accepted traditional breeding techniques. These types of effects also occur spontaneously and in plants generated by conventional breeding (Bradford et al. 2005; Ladics et al. 2015; Schnell et al. 2015). In general, the crossing of plants, each of which will possess a range of innate traits, does not lead to the generation of progeny that have health or environmental effects significantly different from the parents (Weber et al. 2012; Steiner et al. 2013). Therefore, unintended effects resulting from the process of genetic modification will not be considered further in this application.

### Causal pathway

1. The following factors are taken into account when postulating plausible causal pathways to potential harm:
* routes of exposure to the GMOs, the introduced gene(s) and gene product(s)
* potential exposure to the introduced gene(s) and gene product(s) from other sources in the environment
* the environment at the site(s) of release
* agronomic management practices for the GMOs
* spread and persistence of the GM plants (e.g. reproductive characteristics, dispersal pathways and establishment potential)
* tolerance to abiotic conditions (e.g. climate, soil and rainfall patterns)
* tolerance to biotic stressors (e.g. pest, pathogens and weeds)
* tolerance to cultivation management practices
* gene transfer to sexually compatible organism
* gene transfer by horizontal gene transfer (HGT)
* unauthorised activities.
1. Although all of these factors are taken into account, some are not included in risk scenarios because they have been considered in previous RARMPs or are not expected to give rise to substantive risks (see sections 2.2.1 to 2.2.3 below).

#### Gene transfer to sexually compatible relatives

1. As discussed in Chapter 1, Section 6.3.1, *G. hirsutum* is sexually compatible with all GM and non-GM *G. hirsutum* varieties, as well as *G. barbadense*. Therefore, some cross-hybridisation with these plants is inevitable. However, gene transfer to Australian native cotton species is not expected due to genetic incompatibility.
2. Also noted in Chapter 1, Section 6.3.1, gene transfer from the GMO to feral cotton is unlikely to confer an advantage in the absence of cultivation or herbicide use. Therefore, only gene transfer to cultivated *G. hirsutum* and *G. barbadense* will be considered further.

#### Segregation of genes present in the GMO

1. It should be noted that the GMO was generated by conventional crossing between 5 GM cotton lines, so the introduced genes are located in different regions of the plant genome and may segregate independently of one another. Therefore, after any initial outcrossing of the GMO to other cotton, subsequent generations of cotton volunteer plants may contain all the genes from the GMO, genes from one of the GM parental cottons, genes from combinations of some of the parental lines of the GMO, or none of the genes from the GMO. The resulting cottons will have equivalent or less insect resistance and herbicide tolerance than a GMO volunteer plant with all genes, so the assessment for weediness as a result of gene transfer of the introduced genes to other cottons is not affected. Therefore, segregation of the inserted genes will not be considered further.

#### Gene transfer by HGT

1. The potential for horizontal gene transfer (HGT) and any possible adverse outcomes has been reviewed in the literature (Keese, 2008; Philips et al., 2022) and assessed in previous RARMPs. No risk greater than negligible was identified due to the rarity of these events and because the gene sequences (or sequences which are homologous to those in the current application) are already present in the environment and available for transfer via demonstrated natural mechanisms. Therefore, HGT will not be assessed further.

#### Unauthorised activities

1. Previous RARMPs have considered the potential for unauthorised activities to lead to an adverse outcome. The Act provides for substantial penalties for non-compliance and unauthorised dealings with GMOs. The Act also requires the Regulator to have regard to the suitability of the applicant to hold a licence prior to the issuing of a licence. These legislative provisions are considered sufficient to minimise risks from unauthorised activities, and no risk greater than negligible was identified in previous RARMPs. Therefore, unauthorised activities will not be considered further.

### Potential harm

1. Potential harms from GM plants are based on those used to assess risk from weeds (Keese et al., 2014; Virtue, 2008) including:
* harm to the health of people or desirable organisms[[2]](#footnote-3), including toxicity/allergenicity
* reduced biodiversity through harm to other organisms or ecosystems
* reduced establishment or yield of desirable plants
* reduced products or services from the land use
* restricted movement of people, animals, vehicles, machinery and/or water
* reduced quality of the biotic environment (e.g. providing food or shelter for pests or pathogens) or abiotic environment (e.g. negative effects on fire regimes, nutrient levels, soil salinity, soil stability or soil water table).
1. Judgements of what is considered harm depend on the management objectives of the land where the GM plant may be present. A plant species may have different weed risk potential in different land uses such as dryland cropping or nature conservation.

### Postulated risk scenarios

1. Three risk scenarios were postulated and screened to identify any substantive risks. These scenarios are summarised in Table 10 and examined in detail in Sections 2.4.1 – 2.4.3. Postulation of risk scenarios considers potential impacts of the introduced *mCry51Aa2* gene in the GMO, or its products, on people undertaking the dealings, as well as impacts on people and the environment exposed to the GMO or its products as the result of the commercial use or the spread and persistence of plant material, including pollen.
2. In the context of the activities proposed by the applicant and considering both the short and long term, none of the 3 risk scenarios gave rise to any substantive risks that could be greater than negligible.
3. Summary of risk scenarios from dealings with the GMO

| **Risk scenario** | **Risk source** | **Causal pathway** | **Potential harm** | **Substantive risk?** | **Reason** |
| --- | --- | --- | --- | --- | --- |
| 1 | Introduced insect resistance *mCry51Aa2* gene  | Commercial cultivation of the GMO expressing the *mCry51Aa2* gene🡇Exposure of humans and other desirable organisms by ingestion of, or contact with, GM cotton plant material or products, or inhalation of GM cotton pollen | Increased toxicity or allergenicity for humans ORIncreased toxicity to other desirable organisms, including non-target invertebrates | No | * There is limited exposure of humans to the expressed protein.
* The mCry51Aa2 protein has no demonstrated toxicity or allergenicity for humans.
* The mode of action of Cry proteins, including mCry51Aa2, is well understood and is not known to influence the levels of endogenous cotton toxins.
* Consumption of cotton by livestock is limited.
* The mCry51Aa2 protein is toxic to insects from specific orders and other animals or invertebrates outside these orders are not expected to be adversely affected.
 |
| 2 | Introduced insect resistance *mCry51Aa2* gene  | Commercial cultivation of the GMO expressing the *mCry51Aa2* gene🡇Persistence of the GMO seeds in agricultural areas or dispersal of the GMO to nature reserves or intensive use areas 🡇Establishment of population of volunteer GMO in agricultural areas, nature reserves or intensive use areas | Increased toxicity or allergenicity to people ORIncreased toxicity to other desirable organisms, including non-target invertebrates ORReduced establishment or yield of desirable agricultural cropsORReduced establishment or yield of desirable plants in the environmentORReduced utility or quality of the environmentORIncreased reservoir for pest or pathogens | No | * GMO volunteers can be controlled by standard weed management measures.
* The spread and persistence of cotton is restricted by a range of biotic and abiotic factors other than herbivory by insect pests.
* As cotton is unlikely to spread and persist in the environment, it is unlikely to provide a reservoir for pests or pathogens.
* As discussed in Risk Scenario 1, no substantive risk was identified for increased toxicity or allergenicity of the mCry51Aa2 protein.
 |
| 3 | Introduced insect resistance *mCry51Aa2*gene  | Commercial cultivation of the GMO expressing the *mCry51Aa2* gene🡇Pollen from GM plants dispersed outside the cropping areas 🡇Outcrossing with sexually compatible plants🡇Establishment of populations of hybrid GM plants expressing the introduced genes in the environment | Increased toxicity or allergenicity in people or toxicity to desirable organismsORReduced establishment or yield of desirable agricultural cropsORReduced utility or quality of the environmentORIncreased reservoir for pest or pathogens | No | * Cotton is predominantly self-pollinating and has limited ability to outcross.
* Hybrid cottons are unlikely to spread and persist in the environment as the spread and persistence of cotton is restricted by abiotic and biotic factors.
* As discussed in Risk Scenario 1, no substantive risk was identified for increased toxicity or allergenicity of the mCry51Aa2 protein.
* No synergistic or antagonistic effects have been shown between mCry51Aa2 with other 3 insect resistance proteins in the GMO.
* Gene transfer from the GMO to other commercially approved GM cottons is unlikely to produce hybrids with a greater potential to spread and persist in the environment than the GM parental lines or the GMO.
 |

#### Risk scenario 1

| *Risk Source* | Introduced insect resistance *mCry51Aa2* gene  |
| --- | --- |
| *Causal pathway*  | Commercial cultivation of the GMO expressing the *mCry51Aa2* gene🡇Exposure of humans and other desirable organisms by ingestion of, or contact with, GM cotton plant material or products, or inhalation of GM cotton pollen🡇 |
| *Potential harm* | Increased toxicity or allergenicity for humansOR Increased toxicity to other desirable organismsincluding non-target invertebrates |

**Risk source**

1. The source of potential harm for this postulated risk scenario is the introduced insect resistance *mCry51Aa* gene.

**Causal pathway**

1. The applicant proposes that the GMO would be cultivated on a commercial scale in all Australian cotton producing areas. The insect resistance gene *mCry51Aa2* is expressed in leaf, root, seed, pollen, square and boll tissues of the GMO (Chapter 1, Section 5.2.2). People and other desirable organisms may be exposed to the mCry51Aa2 protein through contact, consumption of plant material, plant products, or by inhalation of pollen.
2. The introduced gene and expressed protein are unlikely to be present in cotton products such as cottonseed oil, fibres and linters (FSANZ, 2018b). The public, who consume cottonseed oil and cottonseed linters, or have contact with cotton fabrics, are not expected to be exposed to the introduced gene and its products. Therefore, the people most likely to be exposed to the introduced gene and its product will be workers involved in breeding, cultivating, harvesting, transporting and processing the GMO.
3. Expression of the insect resistance gene in the GMO, or in a GM volunteer, may expose other organisms, including livestock, to the GM plant material through contact or ingestion. The mCry51Aa2 protein may also occur at low levels in the soil as a result of plant material remaining after harvest.
4. Livestock may be exposed to cotton in the form of white cottonseed – seeds left after fibre removal during ginning – and cottonseed meal in feed rations, or through limited grazing of stubble. However, the amount of cotton plant material (both GM and non-GM) that is consumed by livestock is, by necessity, limited due to the presence of endogenous toxins such as gossypol.
5. Other organisms, including wild mammals, birds, soil microbes and non-insect invertebrates would also be exposed to the GMO material in agricultural areas where the GMO is cultivated. The non-target invertebrates may include non-pest insect species that consume the GMO plant, for example, insect predators of pest species, parasitoids, pollinators, or soil biota. These organisms may be exposed to the mCry51Aa2 protein through contact, ingestion or indirectly by feeding on herbivores that have ingested the GMO.

**Potential harm**

1. If humans and other organisms were exposed to the GMO, the potential harms are increased toxicity or allergenicity to humans or increased toxicity to desirable organisms.
2. The mCry51Aa2 protein is unlikely to be toxic to humans, other vertebrates, or the majority of the non-target invertebrates that lack the receptors to which the mCry51Aa2 protein binds (Chapter 1, Section 4.4.2 and Section 5.3.2). As also discussed in Chapter 1, Section 5.3.2, the mCry51Aa2 toxicity studies on CD-1 mice found no adverse effects at high doses. The mCry51Aa2 protein has no sequence similarity to known protein allergens and toxins, and is rapidly degraded in simulated gastric fluid (FSANZ, 2018b). FSANZ assessed the safety of human food derived from MON-88702-4 cotton expressing mCry51Aa2 protein and concluded that it is as safe for human consumption as food derived from conventional cotton (FSANZ, 2018a). It is therefore not expected that the GMO expressing mCry51Aa2 protein would be toxic or allergic to people, or toxic to other desirable organisms.
3. For livestock, cotton (*G. hirsutum*) tissue, particularly the seeds, can be toxic if ingested in excessive quantities due to the presence of endogenous anti-nutritional and toxic factors including gossypol and cyclopropenoid fatty acids (including dihydrosterculic, sterculic and malvalic acids). The presence of gossypol and cyclopropenoid fatty acids in cottonseed limits its use as a protein supplement in animal feed. Ruminants are less affected by these components, which are detoxified by digestion in the rumen, but its use as stockfeed is limited to a relatively small proportion of the diet (Blasi & Drouillard 2002).
4. The presence of the *mCry51Aa2* gene is not expected to affect the levels of endogenous toxins. This is supported by data provided by the applicant (Chapter 1, Section 5.2.4) showing that gossypol and cyclopropenoid fatty acid levels in seed from the GMO are within the recorded range of non-GM cottons and ranges cited in literature. It is not expected that exposure of animals, either through intentional feeding of cottonseed to livestock or occasional, opportunistic feeding of other animals would have an increased risk from exposure to endogenous toxins as a result of the genetic modification.
5. Exposure of non-target invertebrates, particularly arthropods, to the expressed mCry51Aa2 protein may result in death, slowed growth rate, or reduced fecundity if the protein is toxic to these organisms. Arthropods that feed on hemipteran and thysanopteran insects could be adversely affected due to loss of a food source. However, as discussed in Chapter 1, Section 4.4.2, mCry51Aa2 protein shows high degree of specificity to target hemipteran and thysanopteran species and is not expected to harm invertebrates outside these orders. Data from an Australian field study (Chapter 1, Section 4.4.2) indicate that the GMO does not affect the abundance of 13 key beneficial non-target arthropods compared to the BG3 XF control, including non-target insects within the same order as target species.
6. The degradation and persistence of Cry proteins in soil are primarily influenced by microbial activity, which is affected by factors such as soil type, pH, and temperature and other physicochemical and biological properties (APVMA, 2011). For instance, Cry proteins are adsorbed on clay particles and humic substances in soil, which may protect Cry proteins from microbial degradation and allow them accumulate and persist (APVMA, 2011). This adsorption is likely to persist at pH levels below the proteins’ isoelectric point. Despite their persistence under certain conditions, Cry proteins from Bt crops do not show consistent, significant or long-term effects on soil microbial communities or their activities. Additionally, Cry proteins have minimal to no adverse effects on soil-dwelling invertebrates such as earthworm and Collembola (APVMA, 2011). These findings are also supported by the toxicity assessment of mCry51Aa2 (Chapter 1, Section 4.4.2).

**Conclusion**

1. Risk scenario 1 is not identified as a substantive risk, due to limited exposure of humans and other desirable animals to the expressed mCry51Aa2 protein, the lack of toxicity or allergenicity of the mCry51Aa2 protein to humans or toxicity to other desirable organisms including non-target invertebrates and the modifications in the GMO are not expected to affect the levels of endogenous toxins present in non-GM cotton. Therefore, this risk could not be considered greater than negligible and does not warrant further detailed assessment.

#### Risk scenario 2

| *Risk Source* | Introduced insect resistance *mCry51Aa2* gene  |
| --- | --- |
| *Causal pathway*  | Commercial cultivation of GMO expressing the *mCry51Aa2* gene🡇Persistence of the GMO seeds in agricultural areas or dispersal of the GMO to nature reserves or intensive use areas.🡇Establishment of population of volunteer GMO in agricultural areas, nature reserves or intensive use areas.🡇 |
| *Potential harm* | Increased toxicity or allergenicity to people OR Increased toxicity to other desirable organisms including non-target invertebrates ORReduced establishment or yield of desirable agricultural crops ORReduced establishment or yield of desirable plants in the environmentORReduced utility or quality of the environmentORIncreased reservoir for pest or pathogens |

**Risk source**

1. The source of potential harm for this postulated risk scenario is the introduced insect resistance *mCry51Aa2* gene.

**Causal pathway**

1. The applicant proposes that the GMO would be cultivated on a commercial scale in all Australian cotton producing areas. Following harvest, the GMO seeds could remain in agricultural areas, potentially establishing populations of volunteer GM cotton plants in these areas.
2. Seeds from the GMO may be spread from farms into nature reserves by humans, animals, water or extreme weather. Cottonseed is primarily spread off-farm within a localised area during transport of modules to gins, and through irrigation and stormwater runoff. Cottonseed may also be dispersed during extreme weather events, i.e. via wind during wind storms and water during flooding, to adjacent agricultural areas and natural environments (OGTR, 2024).
3. The GMO may be introduced into regions that do not grow the crop through the use of whole cottonseed for supplementation feeding of cattle and sheep, particularly during drought when large piles of cottonseed are placed into a paddock for stock to feed on over the course of several days ([QDAF website](https://www.daf.qld.gov.au/environment/drought/managing-drought/drought-strategies/whole-cottonseed-for-survival-feeding-of-beef-cattle) & [Business Qld website](https://www.business.qld.gov.au/industries/farms-fishing-forestry/agriculture/livestock/animal-welfare/sheep-health/supplementary-feeding/cottonseed), accessed April 2025). Cottonseed may also be introduced into environments around cattle feed lots and dairy farms, where it is used as stockfeed (OGTR, 2024). Cotton harvest equipment can transfer seeds between fields and properties if they are not cleaned prior to transport (CRDC, 2024).
4. Cotton volunteers are most likely to germinate in disturbed habitats, such as stockyards, roadsides along transport routes, and adjacent to waterways (OGTR, 2024). The geographic range of non-GM cotton in Australia is limited by a number of abiotic factors including climate (especially cold stress) and soil compatibility, as well as water and nutrient availability (OGTR, 2024). Feral cotton populations are sparse and ephemeral in all current cotton growing regions of Australia (OGTR, 2024).
5. A study found that even when cotton was sown in cleared sites in northern Australian with high water availability, the cotton plants did not establish stable populations (Eastick and Hearnden, 2006). Modelling of climatic factors limiting cotton persistence indicate that cotton has naturalisation potential only in the coastal regions of north-east Australia. A few small populations of naturalised cotton are reported in northern Australia, but these are not derived from modern cultivars (OGTR, 2024) and these tufted cottons may have a greater ability to survive outside agricultural settings than modern cotton cultivars.
6. Expression of the introduced *mCry51Aa2* insect resistance gene could reduce herbivory by certain hemipteran and thysanopteran species. This could in turn enhance the possibility of survival and establishment of the GMO, leading to increased persistence of the GMO in nature reserves. However, as discussed in Chapter 1, Section 5.2.3, Australian phenotypic characterisations showed no observed changes in the agronomic performance or phenotypic measures of the GMO compared to BG3 XF control. In addition, the germination and dormancy data for MON-88702-4 (Chapter 1, Section 4.4.4) showed that there were no differences in the germination and dormancy characteristics indicative of increased weediness potential of MON-88702-4 cotton compared to non-GM cotton. Additionally, factors other than insect herbivory, in particular abiotic stressors, are the key limiting factors for the survival of cotton outside cultivation, thus the presence of the *mCry51Aa2* gene is unlikely to provide a major advantage to GM cotton volunteers present after or outside cultivation. Taken together, these considerations indicate that the introduced gene *mCry51Aa2* is not expected to increase the spread and persistence of the GM seed.

**Potential Harm**

1. If the GMO expressing *mCry51Aa2* gene remained as a volunteer population in agricultural areas after cultivation, or was able to spread and persist outside in the environment, the postulated harms are increased toxicity or allergenicity to people, increased toxicity to desirable animals, reduced establishment or yield of desirable plants and other organisms that rely on those plants, or increased reservoirs for pathogens or pests.
2. As discussed in Risk scenario 1, no substantiative risk was identified for increased toxicity or allergenicity of the GMO expressing mCry51Aa2 for humans or increased toxicity to desirable organisms other than certain target hemipteran and thysanopteran species.
3. The GMO could reduce establishment or yield of desirable plants, provide a reservoir for pests and pathogens in agricultural settings, or to provide an ongoing source of GM seed for spread into the environment.
4. If GM cotton seed persisted in agricultural areas after harvest and volunteer GM cotton plants emerged, it is not expected that expression of the mCry51Aa2 gene would result in increased persistence of GM volunteers or reduced ability to control volunteer cotton plants. Thus, it is expected that the GM volunteers would be controlled by standard management practice for control of cotton volunteers, such as cultivation or use of herbicides (Chapter 1, Section 6.1). This would limit their ability to persist in agricultural areas, to provide a reservoir for pests or pathogens, or to provide a source of seed for spread outside agricultural areas following harvest.
5. If GM cotton seed was spread and persisted outside agricultural areas, it could reduce the establishment and yield of desirable plants in the environment, thereby reducing plant biodiversity and potentially adversely affecting populations of other organisms that rely on those plants in the environment, or it could act as a reservoir for pests and pathogens. These effects could occur in nature reserves or intensive use areas such as roadsides and waterways. As discussed in Chapter 1 (Section 5.2.3), there was no significant difference between the GMO and non-GM cotton varieties in their responses to a number of abiotic stressors. Therefore, the introduced genes are unlikely to make the GMO more tolerant to abiotic stresses that are naturally encountered in the environment and are unlikely to alter the potential distribution of the GMO plant. Thus, the introduced gene *mCry51Aa2* is not expected to increase the limited potential for cotton to survive outside agricultural settings, or its ability to spread and persist in the broader environment.

**Conclusion**

1. Risk scenario 2 is not identified as a substantive risk because cotton has limited ability to establish outside cultivation, establishment of cotton populations outside intended cropping areas and competition with desirable vegetation is primarily limited by abiotic factors, rather than by the herbivory of certain hemipteran and thysanopteran insects, and the introduced *mCry51Aa2* gene for insect resistance is not expected to affect the GMO’s ability to respond to these limiting factors. Therefore, this risk could not be greater than negligible and does not warrant further detailed assessment.

#### Risk scenario 3

| *Risk Source* | Introduced insect resistance *mCry51Aa2* gene |
| --- | --- |
| *Causal pathway*  | Commercial cultivation of GM cottons expressing the *mCry51Aa2* gene🡇Pollen from the GM plants dispersed outside the cropping areas🡇Outcrossing with sexually compatible plants🡇Establishment of populations of hybrid GM plants expressing the introduced genes in the environment 🡇 |
| *Potential harm* | Increased toxicity or allergenicity in people or toxicity to desirable organismsORReduced establishment or yield of desirable agricultural cropsORReduced utility or quality of the environmentORIncreased reservoir for pest or pathogens |

**Risk source**

1. The source of potential harm for this postulated risk scenario is the introduced insect resistance *mCry51Aa2* gene.

**Causal pathway**

1. The applicant proposes that the GMO would be cultivated on a commercial scale in all Australian cotton producing areas. Outcrossing could occur when the GMO proposed for release and other cotton crops are grown in proximity, with synchronous flowering times.
2. Cotton is predominately self-pollinating, with pollen that is large, sticky and heavy, and generally not dispersed by wind. Pollen can be transported by insect pollinators, chiefly honeybees. For *G. hirsutum* cotton, the only sexually compatible plants are other *G.* *hirsutum* plants or *G. barbadense* plants, as native *Gossypium* species are not sexually compatible with cotton (Chapter 1, Section 6.3.1 – 6.3.2). It is not expected that the introduced insect resistance gene *mCry51Aa* would alter the pollen dispersal characteristics of the GMO proposed for release.
3. Gene transfer to non-GM cotton or other GM cottons, including the parental cottons of the GMO, could occur. However, the resulting progeny would not have an increased range of insect resistance compared to the GMO and as such would not pose any harm other than those that have already been considered for the GMO. As discussed in Chapter 1, Section 5.4, mCry51Aa2 and other 3 insect resistance proteins expressed by the GMO do not show synergistic or antagonistic effects on toxicity to their respective target insect species.
4. The GM cottons Widestrike® (DIR 091) and GlyTol TwinLink Plus® (DIR 143) have been approved for commercial release, although none has been planted commercially. Widestrike® expresses *cry1Ac* and *cry1F*, and GlyTol TwinLink Plus® expresses *cry1Ab*, *cry1Ae* and *vip3Aa19* insect resistance genes. If they are produced commercially in the future, the GMO could cross with these cottons and such crosses could result in progeny with some or all of the *cry* gene(s) from those GM cottons and/or an extra copy of the *cry1Ac* or *vip3Aa19* gene, in addition to the insect resistance genes in the GMO.
5. The *cry1F*, *cry1Ab* and *cry1Ae* gene products share the same mode of action as the Cry proteins produced by the GMO. The 3 gene products show specificity to lepidopteran insects and *cry1Ab* is also toxic to hemipteran insects. In the event of hybridisation, no additional insect orders would be targeted compared to the GMO. There could be additive effects resulting in hybrids with increased resistance to lepidopteran and/or hemipteran insects. However, these additive effects are unlikely to improve the fitness of the hybrid cottons in response to the range of abiotic and biotic factors that limit establishment. Therefore, it is unlikely that any hybrids would be more likely to spread and persist in the environment than the GM parental lines or the GMO.
6. Liberty Link® cotton has also been approved for commercial cultivation, however this cotton does not contain any insect resistance genes, so even if it crossed with the GMO, no insect resistance traits would occur in any hybrids other than those present in the GMO.

**Potential Harm**

1. The potential harms from this risk scenario are increased toxicity or allergenicity to people, increased toxicity to desirable organisms, reduced establishment or yield of desirable plants in agricultural areas or in the natural environment, or an increased reservoir for pathogens or pests.
2. As discussed in Risk scenario 1, no substantive risk was identified for increased toxicity or allergenicity of the GMO for people or increased toxicity to other desirable organisms. Similarly, in hybrids between the GMO and sexually compatible plants, the same consideration would apply.
3. As discussed in Risk scenario 2, the GMO expressing mCry51Aa2 is not expected to be more able to spread and persist in the environment than its GM parental cotton lines. Similarly, in the event of hybridisation with sexually compatible plants, the introduced genetic modifications are not expected to increase the ability of hybrid(s) to spread and persist, or to change their susceptibility to the abiotic factors (particularly frost and water availability) that limit the survival of cotton in the environment. It is also expected standard weed management practices for cotton volunteers in agricultural settings would control hybrids.

**Conclusion**

1. Risk scenario 3 is not identified as a substantive risk because cotton has limited ability to outcross and any hybrids between the GMO and other commercial cottons are not expected to show increased levels of toxicity or allergenicity, or increased ability to spread and persist in the environment. Therefore, this risk could not be greater than negligible and does not warrant further detailed assessment.

## Uncertainty

1. Uncertainty is an intrinsic part of risk and is present in all aspects of risk analysis. This is discussed in detail in the Regulator’s [Risk Analysis Framework](https://www.ogtr.gov.au/resources/publications/risk-analysis-framework-2013) document.
2. Uncertainty is addressed by approaches such as balance of evidence, conservative assumptions, and applying risk management measures that reduce the potential for risk scenarios involving uncertainty to lead to harm. If there is residual uncertainty that is important to estimating the level of risk the Regulator will take this uncertainty into account in making decisions.
3. As mentioned in Chapter 1 (Section 5.1), the RARMP for DIR 147 identified information that may be required to assess an application for a large scale or commercial release of the GMO. This included:

⦁ Molecular, biochemical and phenotypic characterisation of the GM cotton MON-88702-4 including potential for increased toxicity, allergenicity and weediness.

⦁ Potential toxicity to an increased range of insects of the combination of the insecticidal proteins in the GM cotton and the potential for increased weediness.

Further information has been outlined in the relevant sections in Chapter 1 and considered in the risk scenarios in Chapter 2.

1. Uncertainty can arise from a lack of experience growing the GMO expressing the *mCry51Aa2* gene, encoding the mCry51Aa2 protein, which increases resistance to certain hemipteran and thysanopteran insect pests. The GMO has been approved for field trials in Australia under [DIR 147](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-147) and 27 ha has been planted under this licence. In addition, the GMO has been commercially cultivated in the USA on over 172,800 ha following the approval by the USDA-APHIS in 2021. No adverse effects have been reported from these releases. Overall, the level of uncertainty in this risk assessment is considered low and does not impact on the overall estimate of risk.
2. Post release review will be used to address uncertainty regarding future changes to knowledge about the GMO (Chapter 3, Section 4). This is typically used for commercial releases of GMOs, which generally do not have limited duration.

## Risk evaluation

1. Risk is evaluated against the objective of protecting the health and safety of people and the environment to determine the level of concern and, subsequently, the need for controls to mitigate or reduce risk. Risk evaluation may also aid consideration of whether the proposed dealings should be authorised, need further assessment, or require collection of additional information.
2. Factors used to determine which risks need treatment may include:
* risk criteria
* level of risk
* uncertainty associated with risk characterisation
* interactions between substantive risks.
1. Three risk scenarios were postulated whereby the proposed dealings might give rise to harm to people or the environment. The level of risk for each scenario was considered negligible, considering both the short and long term. The principal reasons for these conclusions are summarised in Table 10.
2. The Risk Analysis Framework, which guides the risk assessment and risk management process, defines negligible risks as insubstantial with no present need to invoke actions for their mitigation (OGTR 2013). Therefore, no controls are required to treat these negligible risks. The Regulator considers that the dealings involved in this proposed release do not pose a significant risk to either people or the environment[[3]](#footnote-4).

# Risk management plan

## Background

1. Risk management is used to protect the health and safety of people and to protect the environment by controlling or mitigating risk. The risk management plan addresses risks evaluated as requiring treatment and considers limits and controls proposed by the applicant, as well as general risk management measures. The risk management plan informs the Regulator’s decision-making process and is given effect through proposed licence conditions.
2. Under section 56 of the Act, the Regulator must not issue a licence unless satisfied that any risks posed by the dealings proposed to be authorised by the licence are able to be managed in a way that protects the health and safety of people and the environment.
3. All licences are subject to 3 conditions prescribed in the Act. Section 63 of the Act requires that each licence holder inform relevant people of their obligations under the licence. The other statutory conditions allow the Regulator to maintain oversight of licensed dealings. Section 64 requires the licence holder to provide access to premises to OGTR inspectors and section 65 requires the licence holder to report any information about risks or unintended effects of the dealing to the Regulator on becoming aware of them. Matters related to the ongoing suitability of the licence holder must also be reported to the Regulator.
4. The licence is also subject to any conditions imposed by the Regulator. Examples of the matters to which conditions may relate are listed in section 62 of the Act. Licence conditions can be imposed to limit and control the scope of the dealings and to manage risk to people or the environment. In addition, the Regulator has extensive powers to monitor compliance with licence conditions under section 152 of the Act.

## Risk treatment measures for substantive risks

1. The risk assessment of risk scenarios listed in Chapter 2 concluded that there are negligible risks to people and the environment from the proposed release of the GMO. These risk scenarios were considered in the context of the large scale of the proposed release and the receiving environment. The risk evaluation concluded that no controls are required to treat these negligible risks.

## General risk management

1. All DIR licences issued by the Regulator contain a number of conditions that relate to general risk management. These include conditions relating to:

• applicant suitability

• testing methodology

• identification of the persons or classes of persons covered by the licence

• reporting requirements

• access for the purpose of monitoring for compliance.

### Applicant suitability

1. In making a decision whether or not to issue a licence, the Regulator must have regard to the suitability of the applicant to hold a licence. Under section 58 of the Act, matters that the Regulator must take into account include:
* any relevant convictions of the applicant
* any revocation or suspension of a relevant licence or permit held by the applicant under a law of the Commonwealth, a State or a foreign country
* the capacity of the applicant to meet the conditions of the licence.
1. If a licence were issued, the conditions would include a requirement for the licence holder to inform the Regulator of any circumstances that would affect their suitability.

### Testing methodology

1. If a licence were issued, the licence holder would be required to provide a method to the Regulator for the reliable detection of all events included in the GMO. Bayer has supplied appropriate detection methods for all events included in the GMO as part of the application and as required with previous licences (DIR 145 and DIR 147). Therefore, a requirement to provide detection methods is not included in the draft licence conditions.

### Identification of the persons or classes of persons covered by the licence

1. If a licence were issued, any person, including the licence holder, could conduct any permitted dealing with the GMO.

### Reporting requirements

1. If issued, the licence would oblige the licence holder to report without delay any of the following to the Regulator:

• any additional information regarding risks to the health and safety of people or to the environment associated with the dealings

• any contraventions of the licence by persons covered by the licence

• any unintended effects of the release.

1. The licence holder would also be obliged to submit an Annual Report containing any information required by the licence.
2. There are also provisions that would enable the Regulator to obtain information from the licence holder relating to the progress of the commercial release (see Section 4, below).

### Monitoring for compliance

1. The Act stipulates, as a condition of every licence, that a person who is authorised by the licence to deal with a GMO, and who is required to comply with a condition of the licence, must allow the Regulator, or a person authorised by the Regulator, to enter premises where a dealing is being undertaken for the purpose of monitoring or auditing the dealing.
2. In cases of non-compliance with licence conditions, the Regulator may instigate an investigation to determine the nature and extent of non-compliance. The Act provides for criminal sanctions of large fines and/or imprisonment for failing to abide by the legislation, conditions of the licence or directions from the Regulator, especially where significant damage to the health and safety of people or the environment could result.

## Post release review

1. Regulation 10 requires the Regulator to consider the short and the long term when assessing risks. The Regulator takes account of the likelihood and impact of an adverse outcome over the foreseeable future, and does not disregard a risk on the basis that an adverse outcome might only occur in the longer term. However, as with any predictive process, accuracy is often greater in the shorter rather than longer term.
2. The Regulator engages in ongoing oversight of licences to take account of future findings or changes in circumstances. If a licence was issued, this ongoing oversight would be achieved through post release review (PRR) activities. The three components of PRR are:

• adverse effects reporting system (Section 4.1)

• requirement to monitor specific indicators of harm (Section 4.2)

• review of the RARMP (Section 4.3).

1. The outcomes of these PRR activities may result in no change to the licence or could result in the variation, cancellation or suspension of the licence.

### Adverse effects reporting system

1. Any member of the public can report adverse experiences/effects resulting from an intentional release of a GMO to the OGTR through the Free-call number (1800 181 030), mail (MDP 54 – GPO Box 9848, Canberra ACT 2601) or via email to the OGTR inbox (ogtr@health.gov.au). Reports can be made at any time on any DIR licence. Credible information would form the basis of further investigation and may be used to inform a review of a RARMP (see Section 4.3 below) as well as the RARMPs of future applications involving similar GMOs.

### Requirement to monitor specific indicators of harm

1. Collection of additional specific information on an intentional release provides a mechanism for ‘closing the loop’ in the risk analysis process and for verifying findings of the RARMP, by monitoring the specific indicators of harm that have been identified in the risk assessment.
2. The term ‘specific indicators of harm’ does not mean that it is expected that harm would necessarily occur if a licence was issued. Instead, it refers to measurement endpoints which are expected to change should the authorised dealings result in harm. Should a licence be issued, the licence holder would be required to monitor these specific indicators of harm as mandated by the licence.
3. The triggers for this component of PRR may include risk estimates greater than negligible or significant uncertainty in the risk assessment.
4. The characterisation of the risk scenarios discussed in Chapter 2 did not identify any risks greater than negligible. Therefore, they were not considered substantive risks that warranted further detailed assessment. Uncertainty is considered to be low. No specific indicators of harm have been identified in this RARMP for application DIR 216. However, specific indicators of harm may also be identified during later stages, e.g. following the consideration of comments received on the consultation version of the RARMP, or if a licence were issued, through either of the other components of PRR.
5. Conditions have been included in the draft licence to allow the Regulator to request further information from the licence holder about any matter to do with the progress of the release, including research to verify predictions of the risk assessment.

### Review of the RARMP

1. The third component of PRR is the review of RARMPs after a commercial/general release licence is issued. Such a review would take into account any relevant new information, including any changes in the context of the release, to determine if the findings of the RARMP remained current. The timing of the review would be determined on a case-by-case basis and may be triggered by findings from either of the other components of PRR, or by relevant new scientific information or be undertaken after the authorised dealings have been conducted for some time. If the review findings justified either an increase or decrease in the initial risk estimate(s) or identified new risks to people or to the environment that require management, this could lead to changes to the risk management plan and licence conditions.

## Conclusions of the consultation RARMP

1. The risk assessment concludes that the proposed commercial release of the GMO poses negligible risks to the health and safety of people or the environment as a result of gene technology.
2. The risk management plan concludes that these negligible risks do not require specific risk treatment measures. However, if a licence were to be issued, general conditions are imposed to ensure that there is ongoing oversight of the release.

# [Draft licence conditions](#_Table_of_contents)

## Interpretations and Definitions

1. In this licence:
2. unless defined otherwise in this licence, words and phrases used in this licence have the same meaning as they do in the Act and the Regulations;
3. words importing a gender include every other gender;
4. words in the singular number include the plural and words in the plural number include the singular;
5. expressions used to denote persons generally (such as “person”, “party”, “someone”, “anyone”, “no one”, “one”, “another” and “whoever”), include a body politic or corporate as well as an individual;
6. references to any statute or other legislation (whether primary or subordinate) are a reference to a statute or other legislation of the Commonwealth of Australia as amended or replaced from time to time and equivalent provisions, if any, in corresponding State law, unless the contrary intention appears;
7. where a word or phrase is given a particular meaning, other grammatical forms of that word or phrase have corresponding meanings;
8. specific conditions prevail over general conditions to the extent of any inconsistency.
9. In this licence:

‘**Act**’ means the *Gene Technology Act 2000* (Cth) or the corresponding State legislation under which this licence is issued.

‘**GM**’ means genetically modified.

‘**GMO**’ means the genetically modified organism that is the subject of the dealings authorised by this licence.

‘**OGTR**’ means the Office of the Gene Technology Regulator.

‘**Regulator**’ means the Gene Technology Regulator.

## Licence conditions and obligations

1. This licence does not authorise dealings with the GMO that are otherwise prohibited as a result of the operation of State legislation recognising an area as designated for the purpose of preserving the identity of GM crops, non-GM crops, or both GM crops and non-GM crops, for marketing purposes.
2. This licence remains in force until it is suspended, cancelled or surrendered. No dealings with the GMO are authorised during any period of suspension.
3. The licence holder is Bayer CropScience Ltd Pty.
4. Any person, including the licence holder, may conduct any authorised dealing(s) with the GMO.
5. Except as restricted by condition 3, all dealings with the GMO are permitted.
6. Dealings with the GMO may be conducted in all areas of Australia.
7. This licence authorises dealings with the GMO described in **Attachment A**.

### General obligations of the licence holder

1. The licence holder must notify the Regulator as soon as practicable if any of its contact details change.

*Note: please address correspondence to OGTR.Applications@health.gov.au.*

*Prior to issuing a licence, the Regulator considers suitability of the applicant to hold a licence. The following two conditions address ongoing suitability of the licence holder.*

1. The licence holder must:
2. inform the Regulator as soon as practicable after any of these events occur:
3. any relevant conviction of the licence holder; or
4. any revocation or suspension of a licence or permit held by the licence holder under a law of the Australian Government, a State or a foreign country, being a law relating to the health and safety of people or the environment; or
5. any event or circumstances that would affect the capacity of the licence holder to meet the conditions of the licence; and
6. provide any information related to the licence holder's ongoing suitability to hold a licence, if requested by the Regulator, within the timeframe stipulated by the Regulator.
7. The licence holder must inform any person covered by this licence, to whom a particular condition of the licence applies, of the following:
8. the particular condition (including any variations of it); and
9. the cancellation or suspension of the licence; and
10. the surrender of the licence.

### Provision of new information to the Regulator

*Licence conditions are based on the risk assessment and risk management plan developed in relation to the application using information available at the time of assessment. The following condition requires that any new information that may affect the risk assessment is communicated to the Regulator.*

1. The licence holder must inform the Regulator if the licence holder becomes aware of:
2. additional information as to any risks to the health and safety of people, or to the environment, associated with the dealings authorised by the licence; or
3. any contraventions of the licence by a person covered by the licence; or
4. any unintended effects of the dealings authorised by the licence.

*Note: The Act requires, for the purposes of the above condition, that:*

1. *the licence holder will be taken to have become aware of additional information of a kind mentioned in condition 13 if he or she was reckless as to whether such information existed; and*
2. *the licence holder will be taken to have become aware of contraventions, or unintended effects, of a kind mentioned in condition 13, if he or she was reckless as to whether such contraventions had occurred, or such unintended effects existed.*

*Note: Contraventions of the licence may occur through the action or inaction of a person.*

1. If the licence holder is required to inform the Regulator under condition 13, the Regulator must be informed without delay.

*Note: An example of informing without delay is contact made within a day of becoming aware of new information via the OGTR free call phone number 1800 181 030 or email to OGTR.M&C@health.gov.au.*

1. If at any time the Regulator requests the licence holder to collect and provide information about any matter to do with the progress of the dealings authorised by this licence, including but not confined to:
2. additional information as to any risks to the health and safety of people, or to the environment, associated with the dealings authorised by the licence, whether or not the licence holder has provided information to the Regulator under condition 13(a);
3. any contraventions of the licence by a person covered by the licence, whether or not the licence holder has provided information to the Regulator under condition 13(b);
4. any unintended effects of the dealings authorised by the licence, whether or not the licence holder has provided information to the Regulator under condition 13(c);
5. research, including by way of survey, to verify predictions of the risk assessment, or for any purpose related to risks to the health and safety of people, or to the environment;
6. scientific literature and reports in respect of the GMO authorised by this licence, for a nominated period;
7. details of any refusals of applications for licences or permits (however described) to deal with the GMO made pursuant to the regulatory laws of a foreign country;

and the request is reasonable, having regard to consistency with the Act and relevance to its purpose, then the licence holder must collect the information and provide it to the Regulator at a time and in the manner requested by the Regulator.

*Note: The Regulator may invite the licence holder to make a submission on the reasonability of a request by the Regulator to collect and provide information relevant to the progress of the dealings with the GMO.*

### Obligations of persons covered by the licence

1. If a person is authorised by this licence to deal with the GMO and a particular condition of this licence applies to the dealing by that person, the person must allow the Regulator, or a person authorised by the Regulator, to enter premises where the dealing is being undertaken, for the purposes of auditing or monitoring the dealing.

## Reporting and documentation

### Annual Report

1. The licence holder must provide an annual report to the Regulator by the end of September each year covering the previous financial year. An annual report must include:
2. information about any adverse impacts, unintended effects, or new information relating to risks, to human health and safety or the environment caused by the GMO or material from the GMO;
3. information about the volumes of the GMO grown for commercial purposes, in each State and Territory for each growing season in the period; and
4. information about the volumes of the GMO grown for non-commercial (e.g. research) purposes in each State and Territory for each growing season in the period.

*Note: nil plantings should also be reported under sub-conditions (b) and (c).*

*Note: please address correspondence to OGTR.M&C@health.gov.au*

ATTACHMENT A

**DIR No: 216**

**Full Title:** Commercial release of cotton genetically modified for insect resistance and herbicide tolerance (Bollgard® 3 ThryvOn® cotton with XtendFlex® Technology)

**Licence holder:** Bayer CropScience Pty Ltd

**GMO Description**

**GMO covered by this licence**

Cotton genetically modified by the introduction of only the genes and genetic elements listed below.

**Parent Organism**

Common Name: Cotton

Scientific Name: *Gossypium hirsutum* L.

**Modified traits**

Category: Insect resistance

 Herbicide tolerance

 Selectable marker – Antibiotic resistance

 Selectable marker – Reporter gene expression

Description: The GMO have been genetically modified by the introduction of genes involved in herbicide tolerance and insect resistance. The GMO also contain antibiotic resistance and reporter genes as selectable markers. The event names, introduced genes and selectable markers are listed in Table 1. The GMO proposed for release will also contain short regulatory elements (Table 2).

1. **Introduced genes in the GMO**

| **GM event** | **Gene**  |  **Source** | **Protein function** |
| --- | --- | --- | --- |
| **MON-887Ø2-4** | *mCry51Aa2* | *Bacillus thuringiensis* | hemipteran and thysanopteran insect resistance |
| **MON-15985-7** | *cry1Ac* | *B. thuringiensis* | lepidopteran insect resistance |
|  | *cry2Ab*  | *B. thuringiensis* | lepidopteran insect resistance |
|  | *aad* | *Escherichia coli* | selectable marker – antibiotic resistance (streptomycin) |
|  | *nptII* | *E. coli* | selectable marker – antibiotic resistance (kanamycin) |
|  | *uidA* | *E. coli* | selectable marker – reporter |
| **SYN-IR1Ø2-7** | *vip3Aa19* | *B. thuringiensis* | lepidopteran insect resistance |
|  | *aph4* | *E. coli* | selectable marker – antibiotic resistance (hygromycin) |
| **MON-88913-8** | *cp4 epsps* | *Agrobacterium sp.* strain CP4 | glyphosate herbicide tolerance |
| **MON-887Ø1-3** | *bar* | *Streptomyces hygroscopicus* | glufosinate herbicide tolerance |
|  | *dmo* | *Stenotrophomonas maltophilia* | dicamba herbicide tolerance |

1. Introduced regulatory sequences in the GMO

| **GM event** | **Element function**  |  **Genetic element** | **Source organism** |
| --- | --- | --- | --- |
| **MON-887Ø2-4** | Enhancer | *FMV* | *Figwort mosaic virus (FMV)* |
|  | Promoter and 5’ UTR leader sequence | *Hsp81-2* | *Arabidopsis thaliana* |
|  | 3’ UTR | *35S* | *Cauliflower mosaic virus (CaMV)* |
| **MON-15985-7** | Promoter | *Tn7* | *Escherichia coli*  |
|  | Terminator | *7S 3’* | *Glycine max* |
| **SYN-IR1Ø2-7** | Promoter | *actin 2/ ubiquitin 3* | *A. thaliana* |
|  | Additional element | *ubi3 intron* | *A. thaliana* |
| **MON-88913-8** | Promoter | *P-FMV* | *FMV* |
|  | Promoter | *TSF2/ACT8* | *A. thaliana* |
|  | Terminator | *Rbcs-E9* | *Pisum sativum* – *pea* |
| **MON-887Ø1-3** | Promoter | PC1SV | *Peanut chlorotic streak caulimovirus* |
|  | Terminator | E6 3’ | *Gossypium barbadense* |
| **MON-15985-7; MON-88913-8; MON-887Ø1-3** | Promoter | *35S* | *CaMV* |
| **MON-15985-7; SYN-IR1Ø2-7** | Terminator | *nos* | *Agrobacterium tumefaciens* |
| **MON-15985-7; MON-887Ø1-3** | Additional element | *PetHSP70* | *Petunia x hybrida* |
| **MON-15985-7; MON-88913-8** | Additional element | *Ctp2* | *A. thaliana* |

References

ABARES (2024). Australian Crop Report No. 212 December 2024. (Australian Bureau of Agricultural and Resource Economics and Sciences).

Addison, S.J., Farrell, T., Roberts, G.N., and Rogers, D.J. (2007). Roadside surveys support predictions of negligible naturalisation potential for cotton (*Gossypium hirsutum*) in north-east Australia. Weed Research *47*, 192-201.

APVMA (2011). Public release summary on the evaluation of the new active Bacillus thuringiensis subsp. kurstaki Cry1Ac (synpro) gene and Bacillus thuringiensis subsp. aizawai Cry1F (synpro) gene and their controlling sequences in the product Widestrike Insect Protection Cotton Event 281-24-236/3006-210-23. (Canberra: Australian Pesticides and Veterinary Medicines Authority).

Bachman, P.M., Ahmad, A., Ahrens, J.E., Akbar, W., Baum, J.A., Brown, S., Clark, T.L.*, et al.* (2017). Characterization of the activity spectrum of MON 88702 and the plant-incorporated protectant Cry51Aa2. 834\_16. PloS one *12*, e0169409.

Barberis, L.D. (2017). Dormancy and Germination Evaluation of Cotton MON 88702 Using Seed Produced at U.S. Field Sites During 2015. Report No. MSL 0029036. (Monsanto Study Report (Unpublished)).

Baum, J.A., Sukuru, U.R., Penn, S.R., Meyer, S.E., Subbarao, S., Shi, X., Flasinski, S.*, et al.* (2012). Cotton Plants Expressing a Hemipteran-Active *Bacillus thuringiensis* Crystal Protein Impact the Development and Survival of *Lygus hesperus* (Hemiptera: Miridae) Nymphs. Journal of Economic Entomology *105*, 616.

Bravo, A., Gill, S.S., and Soberon, M. (2007). Mode of action of *Bacillus thuringiensis* Cry and Cyt toxins and their potential for insect control. Toxicon *49*, 423-435.

Brown, A., Brubaker, C., and Kilby, M. (1997). Assessing the risk of cotton transgene escape into Australian Gossypium species. In The Commercialisation of Transgenic Crops: Risk, Benefit and Trade Considerations (Bureau of Resource Sciences), pp. 83-94.

Brubaker, C.L., Brown, A.H.D., Stewart, J.M., Kilby, M.J., and Grace, J.P. (1999). Production of fertile hybrid germplasm with diploid Australian *Gossypium* species for cotton improvement. Euphytica *108*, 199-214.

CottonInfo (2016). Australian cotton production manual 2016. (Cotton Research and Development Corporation, Cotton Seed Distributors and Cotton Australia).

CRDC (2013). WEEDpak. (Narrabri, Australia: Cotton Research and Development Corporation).

CRDC (2024). Cotton Pest Management Guide 2024-2025. (Cotton Research & Development Corporation).

CRDC and CottonInfo (2017). Cotton Pest Management Guide 2017-18. (Narrabri, Australia: Cotton Research and Development Corporation (CRDC) and CottonInfo).

de Maagd, R.A., Bravo, A., and Crickmore, N. (2001). How *Bacillus thuringiensis* has evolved specific toxins to colonize the insect world. Trends in Genetics *17*, 193-199.

Eastick, R., and Hearnden, M. (2006). Potential for weediness of *Bt* cotton (*Gossypium hirsutum*) in northern Australia. Weed Science *54*, 1142-1151.

FSANZ (2002). Final Safety Assessment Application A436 - Oil and linters derived from insect protected cotton containing Event 15985. (Canberra: Food Standards Australia New Zealand).

FSANZ (2004). Final assessment report - Application A509: Food derived from insect protected cotton line COT102. Report No. A509. (Canberra: Food Standards Australia New Zealand).

FSANZ (2005). Final assessment report - Application A553 - Food derived from glyphosate tolerant cotton line MON 88913. (Food Standards Australia New Zealand).

FSANZ (2013). Approval report - Application A1080. Food derived from herbicide-tolerant cotton line MON 88701. (Canberra, Australia: Food Standards Australia New Zealand).

FSANZ (2018a). Approval report – Application A1154. Food derived from insect-protected cotton line MON88702. Report No. A1154. (Food Standards Australia New Zealand).

FSANZ (2018b). Supporting document 1 - Safety assessment – Application A1154 - Food derived from insect-protected cotton line MON88702. (Food Standards Australia New Zealand).

Heap, I. (2025). The international survey of herbicide resistant weeds. Accessed: 4/2/2025. <http://weedscience.org/>.

Invasive Plants and Animals Committee (2015). Noxious weed list for Australian states and territories.

Jerga, A., Chen, D., Zhang, C., Fu, J., Kouadio, J.L., Wang, Y., Duff, S.M.G.*, et al.* (2016). Mechanistic insights into the first Lygus-active ß-pore forming protein. Archives of Biochemistry and Biophysics *600*, 1-11.

Keese, P. (2008). Risks from GMOs due to horizontal gene transfer. Environmental Biosafety Research *7*, 123-149.

Keese, P.K., Robold, A.V., Myers, R.C., Weisman, S., and Smith, J. (2014). Applying a weed risk assessment approach to GM crops. Transgenic Research *23*, 957-969.

Koch, M.S., Ward, J.M., Levine, S.L., Baum, J.A., Vicini, J.L., and Hammond, B.G. (2015). The food and environmental safety of *Bt* crops. Frontiers in Plant Science *6*.

Lemes, A.R.N., Davolos, C.C., Legori, P.C.B.C., Fernandes, O.A., Ferre, J., Lemos, M.V.F., and Desiderio, J.A. (2014). Synergism and antoagonism between *Bacillus thuringiensis* Vip3A and Cry1 proteins in *Heliothis virescens*, *Diatraea saccharalis* and *Spodoptera frugiperda*. PLoS ONE *9*, e107196.

Liu, X., Liu, S., Bai, S., He, K., Zhang, Y., Dong, H., Zhang, T.*, et al.* (2024). Toxicity of Cry- and Vip3Aa-Class Proteins and Their Interactions against Spodoptera frugiperda (Lepidoptera: Noctuidae). Toxins (Basel) *16*.

McClintock, J.T., Schaffer, C.R., and Sjoblad, R.D. (1995). A comparative review of the mammalian toxicity of *Bacillus thuringiensis*-based pesticides. Pesticide Science *45*, 95-105.

OECD (2007). Consensus document on safety information on transgenic plants expressing *Bacillus thuringiensis* - derived insect control protein (Paris, France: Organisation for Economic Co-operation and Development ).

OGTR (2013). Risk Analysis Framework 2013, 4th edn (Canberra: Office of the Gene Technology Regulator).

OGTR (2021). Genetically modified (GM) cotton in Australia. Office of the Gene Technology Regulator, Canberra, Australia.

OGTR (2024). The biology of Gossypium hirsutum L. and Gossypium barbadense L. (cotton) v3.1.

Philips, J.G., Martin-Avila, E., and Robold, A.V. (2022). Horizontal gene transfer from genetically modified plants - Regulatory considerations. Frontiers in Bioengineering and Biotechnology *10*, 971402.

Schnepf, E., Crickmore, N., Van Rie, J., Lereclus, D., Baum, J., Feitelson, J., Zeigler, D.R.*, et al.* (1998). *Bacillus thuringiensis* and its pesticidal crystal proteins. Microbiology and Molecular Biology Reviews *62*, 775-806.

Soberón, M., Gill, S.S., and Bravo, A. (2009). Signaling versus punching hole: How do Bacillus thuringiensis toxins kill insect midgut cells? Cellular and Molecular Life Sciences *66*, 1337-1349.

USDA-APHIS (2002). Determination of Nonregulated Status for Cotton Genetically Engineered for Insect Resistance MON 15985. Report No. 226. (USDA-APHIS).

USDA-APHIS (2004). USDA-APHIS decision on Monsanto Petition 04-086-01p seeking a determination on nonregulated status for glyphosate-tolerant cotton event MON 88913. (Available online).

USDA-APHIS (2005). USDA/APHIS Petition 03-155-01p for Determination of Nonregulated Status for Lepidopteran Resistant Cotton Event COT 102. (Maryland, USA: United States Department of Agriculture Animal and Plant Health Inspection Service).

USDA-APHIS (2012). Petition for the determination of nonregulated status for dicamba and glufosinate-tolerant cotton MON 88701. Report No. 12-CT-244U. (USDA-APHIS).

USDA-APHIS (2021). Determination of Nonregulated Status for Monsanto MON 88702 Cotton. (United States Department of Agriculture - Animal and Plant Health Inspection Service ).

Virtue, J.G. (2008). SA weed risk management guide. (Adelaide: Government of South Australia: Department of Water, Land and Biodiversity Conservation).

Yu, C.G., Mullins, M.A., Warren, G.W., Koziel, M.G., and Estruch, J.J. (1997). The *Bacillus thuringiensis* vegetative insecticidal protein Vip3A lyses midgut epithelium cells of susceptible insects. Applied and Environmental Microbiology *63*, 532-536.

Appendix A: Additional Data tables

1. Expression levels of insect resistance proteins in the GMO during Australian field trials

| **Protein** | **Year** | **Boll-1a,b (μg/g dw)** | **Boll-2** **(μg/g dw)** | **Seed** **(μg/g dw)** | **OSL1****(μg/g dw)** |  **OSL2****(μg/g dw)** |  **OSL3****(μg/g dw)** | **OSL4****(μg/g dw)** | **Pollen****(μg/g dw)** | **Square-1** **(μg/g dw)** | **Square-2** **(μg/g dw)** | **Square-3** **(μg/g dw)** | **Square-4****(μg/g dw)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| mCry51Aa2 | 2018-2019c | 540 ± 28350 - 740 | 460 ± 44250 - 940 | 280 ± 42200 - 370 | 830 ± 9927 - 1200 | 870 ± 40530 - 1100 | 1200 ± 100830 - 1700 | 1100 ± 56670 - 1400 | 42 ± 227.2 - 100 | 1300 ± 88630 - 1800 | 1200 ± 57770 - 1700 | 1300 ± 68990 - 1500 | 1100 ± 54820 - 1500 |
|  | 2019 | 1200 ± 130830 - 1400 | 1200 ± 260400 - 1500 | 180 ± 19130 - 210 | 1400 ± 9.91400 - 1400 | 1400 ± 821200 - 1600 | 1400 ± 521300 - 1500 | 1800 ± 401700 - 1800 | 26 ± NAdNA - NA | 2700 ± 1902500 - 3000 | 2700 ± 2302200 - 3300 | 2200 ± 891900 - 2400 | 2400 ± 832200 - 2500 |
|  | 2019-2020 | 1000 ± 80630 - 1500 | 660 ± 46410 - 1000 | 530 ± 23350 - 700 | 1900 ± 851100 - 2400 | 1800 ± 1101100 -2700 | 1700 ± 150890 - 2800 | 990 ± 50740 - 1500 | 26 ± 141.8 - 54 | 3800 ± 1602500 - 4800 | 4300 ± 953400 - 5000 | 3900 ± 2202400 - 5900 | 3700 ± 1302800 - 4700 |
| Cry1Ac | 2018-2019 | 15 ± 0.4212 - 18 | 14 ± 0.969.0 - 19 | 16 ± 2.89.4 - 22 | 26 ± 3.40.47 - 45 | 28 ± 2.912 - 43 | 23 ± 0.9919 - 27 | 16 ± 0.8212 - 22 | 1.3 ± 0.540.41 - 2.6 | 26 ± 1.319 - 33 | 18 ± 1.59.6 - 30 | 16 ± 0.7312 - 19 | 13 ± 0.4811 - 16 |
|  | 2019 | 14 ± 0.4014 - 16 | 11 ± 2.34.4 - 15 | 26 ± 0.7224 - 28 | 40 ± 3.534 - 50 | 55 ± 6.438 - 69 | 31 ± 2.028 - 37 | 39 ± 0.8537 - 41 | 1.7 ± NANA - NA | 48 ± 3.844 - 55 | 38 ± 3.033 - 47 | 25 ± 0.7723 - 27 | 22 ± 0.5121 - 24 |
|  | 2019-2020 | 16 ± 1.47.0 - 28 | 20 ± 1.015 - 29 | 23 ± 1.814 - 41 | 50 ± 2.235 - 63 | 41 ± 3.220 - 60 | 30 ± 5.73.2 - 63 | 39 ± 3.320 - 74 | 0.81 ± 0.320.44 - 1.8 | 52 ± 3.035 - 76 | 27 ± 0.8920 - 34 | 22 ± 1.016 - 31 | 24 ± 0.9617 - 32 |
| Cry2Ab | 2018-2019 | 320 ± 26220 - 570 | 390 ± 30220 - 600 | 770 ± 110530 - 1000 | 550 ± 739.9 - 930 | 470 ± 46170 - 720 | 420 ± 24310 - 490 | 250 ± 18100 - 360 | 43 ± 312.2 - 100 | 500 ± 26320 - 670 | 390 ± 24220 - 500 | 370 ± 20270 - 460 | 280 ± 8.3250 - 340 |
|  | 2019 | 130 ± 1989 - 180 | 120 ± 2355 - 160 | 720 ± 96520 - 940 | 390 ± 66250 - 570 | 260 ± 53110 - 350 | 90 ± 8.475 - 110 | 390 ± 44310 - 490 | 54 ± NANA - NA | 620 ± 19580 - 640 | 470 ± 32420 - 560 | 280 ± 12250 - 310 | 310 ± 14290 - 350 |
|  | 2019-2020 | 300 ± 24180 - 500 | 360 ± 4282 - 580 | 1100 ± 77810 - 1900 | 1400 ± 82930 - 1900 | 920 ± 11098 - 1700 | 550 ± 110110 - 1200 | 510 ± 52280 - 870 | 19 ± 110.50 - 44 | 1000 ± 55630 - 1500 | 800 ± 28620 - 1000 | 630 ± 30450 - 880 | 540 ± 25420 - 740 |
| Vip 3Aa19 | 2018-2019 | 5.9 ± 0.774.2 - 12 | <LOQe ± NANA - NA | <LOQ ± NANA - NA | 44 ± 1.931 - 56 | 48 ± 3.031 - 66 | 32 ± 1.028 - 36 | 30 ± 1.425 - 36 | <LOQ ± NANA - NA | 45 ± 6.316 - 110 | 40 ± 3.818 - 71 | 34 ± 3.026 - 53 | 24 ± 2.214 - 39 |
|  | 2019 | 6.2 ± 14.5 – 8.0 | 6.2 ± 0.894.4 - 8.4 | <LOQ ± NANA - NA | 170 ± 11140 - 190 | 110 ± 9.483 - 120 | 54 ± 7.732 - 66 | 110 ± 4.5100 - 120 | <LOQ ± NANA - NA | 130 ± 11110 - 150 | 65 ± 6.158 - 83 | 57 ± 3.139 - 97 | 53 ± 444 - 62 |
|  | 2019-2020 | <LOQ ± NANA - NA | <LOQ ± NANA - NA | <LOQ ± NANA - NA | 110 ± 5.169 - 140 | 110 ± 7.958 - 160 | 110 ± 6.883 - 150 | 110 ± 1245 - 240 | <LOQ ± NANA - NA | 91 ± 3.563 - 120 | 72 ± 3.648 - 93 | 57 ± 3.839 - 97 | 66 ± 2.150 - 77 |

a Boll-1 and Boll-2, collected at 14 days after first flower and cutout stages; seed, collected at maturity; Leaf – OSL1, OSL2, OSL3 and OSL4, collected at Match head square, Pre flower, Peak flower and Cutout stages, respectively; pollen, collected at peak bloom stage; Square 1, 2, 3 and 4 collected at Match head square, Pre flower, Peak flower and Cutout stages, respectively.

b Data are shown as the mean ± standard deviation, followed by the range of values recorded across all samples

c 2018-2019: summer; 2019: winter; 2019-2020: summer

d NA=not applicable

e LOQ=limit of quantitation (lowest value of concentration that can be quantified with acceptable precision and accuracy)

1. Expression levels of herbicide tolerance proteins in the GMO during Australian field trials

| **Protein** | **Year** | **Boll-1a.b** **(μg/g dw)** | **Boll-2** **(μg/g dw)** | **Seed** **(μg/g dw)** | **OSL1****(μg/g dw)** |  **OSL2****(μg/g dw)** |  **OSL3****(μg/g dw)** | **OSL4****(μg/g dw)** | **Pollen****(μg/g dw)** | **Square-1** **(μg/g dw)** | **Square-2** **(μg/g dw)** | **Square-3** **(μg/g dw)** | **Square-4****(μg/g dw)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| DMO | 2018-2019c | 38 ± 2.130 - 58 | 34 ± 1.127 - 43 | 16 ± 3.08.7 - 21 | 88 ± 112.1 - 120 | 110 ± 5.086 - 150 | 67 ± 3.652 - 85 | 110 ± 4.182 - 130 | 15 ± 3.312 - 19 | 53 ± 5.416 - 83 | 57 ± 4.526 - 99 | 100 ± 3.984 - 120 | 97 ± 6.671 - 160 |
|  | 2019 | 86 ± 1.383 - 89 | 100 ± 2335 - 140 | 18 ± 0.6717 - 20 | 280 ± 13250 - 300 | 250 ± 11220 - 270 | 170 ± 14130 - 200 | 240 ± 8.8230 - 270 | 14 ± NAdNA - NA | 450 ± 13420 - 460 | 410 ± 17380 - 460 | 410 ± 13380 - 440 | 410 ± 13380 - 440 |
|  | 2019-2020 | 89 ± 4.654 - 120 | 140 ± 6.984 - 190 | 21 ± 1.89.8 - 38 | 250 ± 11180 - 320 | 370 ± 13290 - 480 | 200 ± 2839 - 390 | 360 ± 24260 - 580 | <LOQe ± NANA - NA | 420 ± 6.9370 - 490 | 480 ± 9.8410 - 560 | 450 ± 10400 - 540 | 490 ± 12360 - 550 |
| PAT | 2018-2019 | 1.2 ± 0.0710.81 - 1.6 | 0.65 ± 0.090.26 - 1.2 | 3.9 ± 0.971.7 - 5.7 | 3.3 ± 0.430.19 - 5.2 | 3.1 ± 0.301.0 - 4.6 | 2.9 ± 0.102.5 - 3.3 | 2.4 ± 0.190.90 - 3.2 | <LOQ ± NANA - NA | 2.7 ± 0.201.5 - 3.7 | 2.6 ± 0.201.4 - 4.3 | 3.2 ± 0.132.8 - 4.0 | 2.8 ± 0.112.2 - 3.7 |
|  | 2019 | 0.88 ± 0.040.79 - 0.99 | 0.68 ± 0.110.44 - 0.87 | 5.9 ± 0.145.6 - 6.3 | 6.2 ± 0.495.1 - 7.5 | 5.1 ± 0.812.8 - 6.5 | 1.7 ± 0.161.4 - 2.2 | 3.5 ± 0.232.8 - 3.9 | <LOQ ± NANA - NA | 5.7 ± 0.744.6 - 7.1 | 4.5 ± 0.284.0 - 5.3 | 4.1 ± 0.0834.0 - 4.3 | 3.9 ± 0.133.6 - 4.2 |
|  | 2019-2020 | 1.0 ± 0.080.47 - 1.5 | 1.0 ± 0.0850.57 - 1.7 | 13 ± 0.787.8 - 19 | 5.9 ± 0.204.4 - 7.2 | 5.9 ± 0.303.9 - 7.9 | 3.4 ± 0.650.55 - 6.4 | 4.9 ± 0.401.9 - 7.8 | <LOQ ± NANA - NA | 4.5 ± 0.173.0 - 5.7 | 5.3 ± 0.194.5 - 7.0 | 4.8 ± 0.173.6 - 6.0 | 5.5 ± 0.234.2 - 7.3 |
| CP4 EPSPS | 2018-2019 | 550 ± 22400 - 700 | 400 ± 44200 - 800 | 280 ± 42200 - 370 | 1100 ± 15026 - 1800 | 1200 ± 96600 - 1700 | 1100 ± 71700 - 1300 | 840 ± 41600 - 1200 | 41 ± 227.1 - 100 | 550 ± 29400 - 700 | 560 ± 23380 - 790 | 620 ± 26480 - 710 | 530 ± 17420 - 620 |
|  | 2019 | 660 ± 61490 - 770 | 680 ± 170190 - 960 | 220 ± 29150 - 290 | 1800 ± 2001300 - 2100 | 2000 ± 2701200 - 2400 | 1500 ± 781300 - 1600 | 1700 ± 251600 - 1700 | 51 ± NANA - NA | 1100 ± 671100 - 1300 | 1100 ± 62980 - 1300 | 870 ± 43750 - 930 | 1000 ± 46890 - 1100 |
|  | 2019-2020 | 790 ± 66300 - 1200 | 890 ± 53680 - 1300 | 440 ± 17300 - 560 | 2400 ± 851600 - 2800 | 2200 ± 180420 - 3100 | 1500 ± 140560 - 2200 | 1900 ± 901400 - 2700 | 39 ± 187.4 - 76 | 1300 ± 43940 - 1500 | 1400 ± 301200 - 1600 | 1200 ± 44840 - 1500 | 1100 ± 34880 - 1400 |

a Boll-1 and Boll-2, collected at 14 days after first flower and cutout stages; seed, collected at maturity; Leaf – OSL1, OSL2, OSL3 and OSL4, collected at Match head square, Pre flower, Peak flower and Cutout stages, respectively; pollen, collected at peak bloom stage; Square 1, 2, 3 and 4 collected at Match head square, Pre flower, Peak flower and Cutout stages, respectively.

b Data are shown as the mean ± standard deviation, followed by the range of values recorded across all samples

c 2018-2019: summer; 2019: winter; 2019-2020: summer

d NA=not applicable

e LOQ=limit of quantitation (lowest value of concentration that can be quantified with acceptable precision and accuracy)

1. Phenotypic characterisation of the GMO (Australia)

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | Season | Mean (SE) |  |
|  |  | GMO | Controla |
| Early Stand Countb | 2018-19 | 9.5 (0.77) | 11.3 (0.97) |
|  | 2019-20 | 15.8 (1.22) | 13.5 (0.70) |
| Late Stand Count | 2018-19 | 10.3 (0.7) | 11.4 (0.97) |
|  | 2019-20 | 15.0 (1.27) | 13.1 (0.51) |
| Vigourc | 2018-19 | 4.2 (0.46) | 4.8 (0.28) |
|  | 2019-20 | 6.4 (0.45) | 6.5 (0.51) |
| Plant Heightd 2 | 2018-19 | 15.9 (1.29) | 16.8 (1.52) |
|  | 2019-20 | 16.5 (1.90) | 17.5 (2.06) |
| Plant Height 3 | 2018-19 | 39.8 (2.59) | 41.3 (3.20) |
|  | 2019-20 | 35.8 (4.49) | 38.4 (4.72) |
| Plant Height 4 | 2018-19 | 66.7 (2.24) | 70.9 (2.88) |
|  | 2019-20 | 63.1 (3.29) | 65.4 (3.53) |
| Plant Height 5 | 2018-19 | 70.1 (2.12) | 71.2 (3.36) |
|  | 2019-20 | 77.7 (1.99) | 81.1 (2.03)\* |
| Plant Height 6 | 2018-19 | 75.8 (3.39) | 77.3 (3.04) |
|  | 2019-20 | No Data | No Data |
| Plant Height 7 | 2018-19 | 77.9 (3.59) | 79.2 (2.87) |
|  | 2019-20 | No Data | No Data |
| Nodesd 2 | 2018-19 | 6.9 (0.51) | 7.3 (0.58) |
|  | 2019-20 | 6.2 (0.47) | 6.6 (0.50)\* |
| Nodes 3 | 2018-19 | 12.2 (0.41) | 12.9 (0.34) |
|  | 2019-20 | 11.1 (0.67) | 11.9 (0.67)\* |
| Nodes 4 | 2018-19 | 18.0 (0.34) | 18.6 (0.36) |
|  | 2019-20 | 15.9 (0.53) | 17.0 (0.44)\* |
| Nodes 5 | 2018-19 | 18.7 (0.62) | 19.5 (0.50) |
|  | 2019-20 | 19.1 (0.43) | 20.1 (0.36)\* |
| Nodes 6 | 2018-19 | 17.3 (0.39) | 18.9 (0.30)\* |
|  | 2019-20 | No Data | No Data |
| Nodes 7 | 2018-19 | 17.7 (0.46) | 19.6 (0.32)\* |
|  | 2019-20 | No Data | No Data |
| NAWFe at 7 DAF | 2018-19 | 7.2 (0.31) | 7.3 (0.23) |
|  | 2019-20 | 7.0 (0.19) | 7.1 (0.24) |
| NAWF at 14 DAF | 2018-19 | 6.4 (0.40) | 6.3 (0.41) |
|  | 2019-20 | 6.1 (0.19) | 6.0 (0.19) |
| NAWF at 21 DAF | 2018-19 | 4.4 (0.54) | 4.4 (0.51) |
|  | 2019-20 | 4.4 (0.26) | 4.4 (0.28) |
| Yield (kg lint/ha) | 2018-19 | 1805.0 (121.24) | 1956.0 (139.98) |
|  | 2019-20 | 2311.0 (137.20) | 2571.0 (142.13) |
| Length (cm) | 2018-19 | 1.14 (0.01) | 1.16 (0.01) |
| Micronaire | 2018-19 | 4.5 (0.12) | 4.4 (0.08) |
| Strength | 2018-19 | 29.1 (0.61) | 30.9 (0.66) |

a Control isMON 15985 × COT102 × MON 88701 × MON 88913

b 21 days after planting (DAP) the number of emerged plants was counted across 2 x 1 m2 areas in each plot.

c 21 DAP, plant vigour was rated across 2 × 1 m2 areas of each plot using a rating scale of 1-9 where: 1 is excellent vigour and 9 is poor vigour.

d At 21 DAP, ten plants were non-systematically selected and tagged. From this date, every 21 days the plant height (cm) was measured from the soil to the growing tip, and the number of nodes counted from the cotyledons (cotyledon position being zero) to the last fully unfurled leaf.

e NAWF (Nodes Above White Flower): The approximate date of first flower of each plot was recorded. The number of nodes from the upper most first position white flower to the terminal bud was recorded on ten non-systematically selected plants from each plot once a week for 3 consecutive weeks, beginning 7 days after flowering (DAF).

\*Indicates a statistically significant difference between the test and the control

1. Compositional analysis for cotton seed from the GMO and non-GM cotton control

| Component | Sample | Mean (SE)a | Mean Range(Min. - Max.) | p-value | Comparative Rangeb |
| --- | --- | --- | --- | --- | --- |
| Protein and Amino Acids |  |  |  |  |  |
| Protein | GMO | 24.24 (0.42) | 22.19- 26.57 | <0.001 | 19.19-32.97 |
|  | Control | 25.66 (0.42) | 23.93 - 27.93 |  |  |
| Alanine | GMO | 0.91 (0.015) | 0.79 - 1.03 | <0.001 | 0.69-1.29 |
|  | Control | 0.96 (0.015) | 0.87 - 1.02 |  |  |
| Arginine | GMO | 2.19 (0.058) | 1.80 - 2.57 | 0.002 | 1.76-3.93 |
|  | Control | 2.43 (0.058) | 2.08 - 2.69 |  |  |
| Aspartic acid | GMO | 2.07 (0.048) | 1.73 - 2.42 | <0.001 | 1.51-3.21 |
|  | Control | 2.24 (0.048) | 2.04 - 2.46 |  |  |
| Cystine | GMO | 0.45 (0.018) | 0.35 - 0.65 | 0.917 | 0.288-0.557 |
|  | Control | 0.45 (0.018) | 0.38 - 0.69 |  |  |
| Glutamic acid | GMO | 4.59 (0.086) | 3.92 - 5.44 | <0.001 | 3.04-6.72 |
|  | Control | 5.05 (0.086) | 4.59 - 5.46 |  |  |
| Glycine | GMOControl | 0.90 (0.015)0.96 (0.015) | 0.78 - 1.040.87 - 1.05 | 0.014 | 0.73-1.32 |
| Histidine | GMOControl | 0.60 (0.012)0.64 (0.012) | 0.52 - 0.670.58 - 0.70 | 0.004 | 0.452-0.985 |
| Isoleucine | GMOControl | 0.70 (0.011)0.73 (0.011) | 0.62 - 0.780.67 - 0.77 | 0.002 | 0.58-1.05 |
| Leucine | GMOControl | 1.28 (0.021)1.34 (0.021) | 1.13 - 1.451.22 - 1.43 | 0.004 | 1.01-1.86 |
| Lysine | GMOControl | 1.10 (0.019)1.16 (0.019) | 0.94 - 1.231.01 - 1.29 | 0.015 | 0.84-1.46 |
| Methionine | GMOControl | 0.30 (0.014)0.33 (0.014) | 0.14 - 0.410.24 - 0.40 | 0.064 | 0.29-0.49 |
| Phenylalanine | GMO | 1.09 (0.026) | 0.92 - 1.27 | 0.028 | 0.88-1.76 |
|  | Control | 1.17 (0.026) | 1.02 - 1.31 |  |  |
| Proline | GMO | 0.81 (0.014) | 0.72 - 0.94 | <0.001 | 0.60-1.37 |
|  | Control | 0.87 (0.014) | 0.80 - 0.93 |  |  |
| Serine | GMO | 0.97(0.018) | 0.83 - 1.12 | 0.013 | 0.74-1.39 |
|  | Control | 1.03 (0.018) | 0.91 - 1.10 |  |  |
| Threonine | GMO | 0.73 (0.011) | 0.65 - 0.82 | 0.047 | 0.55-1.06 |
|  | Control | 0.76 (0.011) | 0.70 - 0.81 |  |  |
| Tryptophan | GMO | 0.28 (0.0083) | 0.24 - 0.34 | 0.032 | 0.162-0.519 |
|  | Control | 0.31 (0.0083) | 0.28 - 0.37 |  |  |
| Tyrosine | GMO | 0.47 (0.011) | 0.42 - 0.55 | 0.030 | 0.47-1.00 |
|  | Control | 0.50 (0.011) | 0.44 - 0.56 |  |  |
| Valine | GMO | 0.94 (0.015) | 0.83 - 1.05 | 0.004 | 0.76-1.49 |
|  | Control | 0.99 (0.015) | 0.91 - 1.05 |  |  |
| Total Fat and Fatty Acids (FA) |  |  |  |  |  |
| Total fat  | GMO | 19.37 (0.30) | 16.38 - 20.98 | 0.521 | 15.05-27.90 |
|  | Control | 19.59 (0.30) | 17.17-21.14 |  |  |
| Myristic acid | GMO | 0.66 (0.014) | 0.61 - 0.71 | 0.197 | 0.426-2.400 |
| (% Total FA) | Control | 0.67 (0.014) | 0.61 - 0.77 |  |  |
| Palmitic acid | GMO | 19.66 (0.34) | 18.30 - 21.46 | <0.001 | 15.11-27.90 |
| (% Total FA) | Control | 21.02 (0.34) | 19.84 - 22.18 |  |  |
| Palmitoleic acid | GMO | 0.64 (0.021) | 0.53 - 0.76 | <0.001 | 0.375-1.190 |
| (% Total FA) | Control | 0.55 (0.021) | 0.48- 0.65 |  |  |
| Stearic acid | GMO | 2.46 (0.079) | 2.09 - 2.66 | <0.001 | 0.20-3.54 |
| (% Total FA) | Control | 2.30 (0.079) | 2.01 - 2.56 |  |  |
| Oleic acid  | GMO | 18.06 (0.71) | 16.34 - 20.60 | <0.001 | 12.8-25.4 |
| (% Total FA) | Control | 17.00 (0.71) | 15.51 - 19.24 |  |  |
| Linoleic acid | GMO | 57.00 (0.92) | 53.29 - 60.39 | 0.668 | 42.5-63.0 |
| (% Total FA) | Control | 57.09 (0.92) | 53.69 - 59.54 |  |  |
| Linolenic acid | GMO | 0.17 (0.014) | 0.13 - 0.28 | 0.147 | 0.10-0.64 |
| (% Total FA) | Control | 0.16 (0.014) | 0.13 - 0.24 |  |  |
| Carbohydrates |  |  |  |  |  |
| Carbohydrates by  | GMO | 52.49 (0.43) | 49.20 - 54.73 | <0.001 | 39.04-59.25 |
| calculation | Control | 50.88 (0.43) | 48.75 - 53.22 |  |  |
| ADF | GMO | 35.09 (0.52) | 32.45 - 37.72 | 0.062 | 19.74-38.95 |
|  | Control | 34.34 (0.52) | 31.27 - 36.28 |  |  |
| NDF | GMO | 43.67 (0.53) | 40.60 - 46.93 | 0.655 | 25.56-51.87 |
|  | Control | 43.51 (0.53) | 40.93 - 45.56 |  |  |
| TDF | GMO | 44.50 (0.49) | 42.14- 48.15 | 0.044 | 33.69-53.50 |
|  | Control | 43.56 (0.49) | 41.65 - 46.07 |  |  |
| Ash and Minerals |  |  |  |  |  |
| Ash | GMO | 3.89 (0.19) | 3.21-4.43 | 0.734 | 3.006-5.476 |
|  | Control | 3.88 (0.19) | 2.92 - 4.35 |  |  |
| Calcium | GMO | 0.14 (0.0096) | 0.11-0.17 | 0.005 | 0.070-0.326 |
|  | Control | 0.12 (0.0096) | 0.083 - 0.15 |  |  |
| Phosphorus | GMO | 0.65 (0.060) | 0.44 - 0.84 | 0.416 | 0.384-0.992 |
|  | Control | 0.66 (0.060) | 0.42 - 0.85 |  |  |
| Vitamins |  |  |  |  |  |
| Vitamin E | GMO | 106.50 (7.02) | 81.09 - 135.09 | 0.544 | 26.57-197.24 |
| (mg/kg dw) | Control | 105.21 (7.02) | 77.77 - 125.51 |  |  |
| Anti-nutrients |  |  |  |  |  |
| Total gossypol  | GMO | 0.91 (0.039) | 0.75-1.12 | 0.295 | 0.350-1.613 |
|  | Control | 0.95 (0.039) | 0.75 - 1.19 |  |  |
| Free gossypol  | GMO | 0.72 (0.022) | 0.54 - 0.84 | 0.545 | 0.384-1.418 |
|  | Control | 0.73 (0.022) | 0.52 - 0.85 |  |  |
| Malvalic acid | GMO | 0.68 (0.030) | 0.59 - 0.91 | 0.032 | 0.112-0.854 |
| (% Total FA) | Control | 0.63 (0.030) | 0.56 - 0.73 |  |  |
| Sterculic acid | GMO | 0.25 (0.0085) | 0.22 - 0.30 | 0.062 | 0.061-0.556 |
| (% Total FA) | Control | 0.23 (0.0085) | 0.20 - 0.26 |  |  |
| Dihydrosterculic acid | GMO | 0.44 (0.015) | 0.36 - 0.51 | <0.001 | 0.031-0.325 |
| (% Total FA) | Control | 0.35 (0.015) | 0.30 - 0.39 |  |  |

a All measures expressed as % dw unless stated

b ILSI range is from ILSI Crop Composition Database, 2016 (Accessed February 24, 2017).

Appendix B: [Summary of submissions](#_Table_of_contents)

The Regulator received several submissions from prescribed experts, agencies and authorities[[4]](#footnote-5) on matters relevant to preparation of the RARMP. All issues raised in submissions relating to risks to the health and safety of people and the environment were considered. These issues, and where they are addressed in the consultation RARMP, are summarised below.

| **Submission** | **Summary of issues raised** | **Comment** |
| --- | --- | --- |
| 1 | Agrees that the following should be included in the RARMP: |  |
| * the potential for the GM cotton to be harmful to the environment
* the potential for the GM cotton to be harmful to people through toxicity or allergenicity
* the potential for the GM cotton to be harmful to other organisms, particularly beneficial invertebrates, through toxicity
* the potential for gene flow to other cottons
* whether commercial release is likely to result in changes to agricultural practices that may have an environmental impact.
 | These issues have been considered in Chapters 1 and 2 of the Risk Assessment and Risk Management Plan (RARMP).  |
| Advises that the Regulator should further consider risks associated with the potential for antibiotic resistance gene transfer.  | The GMO contains 3 antibiotic resistance genes, which originated from one of the GM parental lines that has been already approved for commercial release. No additional antibiotic resistance genes are included in the GMO. The genes from the GM parental lines were previously assessed by the Regulator and found to pose negligible risk to human health or to the environment. Literature searches conducted to address this concern did not find any new information to change this conclusion. For further information, please refer to Chapter 2, Section 2.1 and 2.2.3, of the RARMP. |
| 2 | No advice or comments on the RARMP. | Noted. |
| 3 | No specialist scientist expertise available. Concerned about: | Noted. |
| The GM cotton is resistant to common herbicides such as glyphosate. Concerned that frequent and heavy use of these herbicides leading to the development of resistant weeds, spread beyond farms, difficulty and expense of control. | Issues relating to herbicide use are outside the scope of the *Gene Technology Act 2000* (The Act). Herbicide resistance issues come under the regulatory oversight of the Australian Pesticides and Veterinary Medicines Authority (APVMA). A range of issues, including effects on human health, weed resistance management and environmental impacts are considered by the APVMA in assessing agricultural chemicals for registration. In Australia, herbicide resistance is an important matter of general agricultural industry concern and is not confined to herbicides used in GM crops. Discussion of Integrated Weed Management, which is designed to limit the development of herbicide resistance in weed populations, is included in Chapter 1, Section 6.1 of the RARMP. |
| The GM insecticidal traits and associated herbicide applications could indirectly affect non-target organisms, including beneficial insects and soil microbes. | Three of the *Bacillus thuringiensis* (Bt) derived insect resistance proteins which confer resistance to lepidopteran insects (moths) have been extensively assessed previously for commercial release (DIR 145). This assessment concluded that these genes and their expressed proteins pose negligible risks to human health or the environment. No new information was found to change these conclusions. Cotton expressing the Bt-derived insect resistance gene that confers resistance to hemipteran and thysanopteran insects (aphids and thrips) has been assessed previously by the Regulator for limited and controlled release (DIR 147). Information provided and reviewed in the current application indicates this insect resistance gene is not toxic to desirable organisms, including non-target invertebrates and soil microbes (Chapter 1 section 4.4.2) and is considered in the risk scenarios (Chapter 2 of the RARMP). As noted above, the APVMA has regulatory responsibility for agricultural chemicals, including herbicides, in Australia. |
| 4 | Unable to reach OGTR via the phone number. Requests information about the process to provide formal advice. | Response provided by email to clarify the process.  |
| Asks whether the documents attached to the request for comment can be shared publicly. | Confirmed that documents provided as part of the request for comment are public documents and can be shared.  |
| 5 | Noted that this application is similar to previous GM cotton trials and approvals by the OGTR. No further comment was provided.  | Noted. |
| 6 | Considered the proposed risk management measures adequate.  | Noted. |
| Noted that removing the myc tag from the proteins could reduce the risk of introducing new potential allergens.  | There is no myc tag attached to any of the introduced proteins in the GM cotton. |
| No additional concerns at this point, notes there will be another opportunity to provide feedback during the draft RARMP consultation. | Noted. |
| 7 | Concerns about: |  |
| * reliance on specific branded chemical pesticides linked to this GM crop.
 | Issues relating to herbicide use are outside the scope of the Regulator’s assessments. The APVMA has regulatory responsibility for agricultural chemicals, including herbicides, in Australia. |
| * potential contamination of nearby farms affecting organic certification
 | Consideration of economic or trade issues is outside the scope of the Act. APVMA requirements, State-specific requirements or industry protocols address these issues. |
|  | * the need for resistance management with three chemicals listed in the application
 | As noted above, the APVMA has regulatory responsibility for agricultural chemicals, including herbicides, in Australia. Discussion of Integrated Weed Management is also included in the RARMP (Chapter 1, Section 6.1). |
|  | * Seeks clarification on how the crop would be managed if it became a weed.
 | The potential for weediness of the GM cotton is considered in risk scenarios 2 and 3 (Chapter 2). It is not expected that expression of the introduced genes would result in increased spread and persistence of GM volunteers or reduced the ability to control volunteer cotton plants. Thus, the risk of weediness for the GM cotton is considered to be no greater than currently-grown GM and non-GM cotton varieties and any GM volunteers would be controlled by standard weed management practices for cotton volunteers. |

1. The title of the project as supplied by the applicant is “Commercial release of cotton genetically modified for insect resistance and herbicide tolerance” [↑](#footnote-ref-2)
2. Desirable organisms are those that are valued and should be protected, while undesirable organisms cause harm and should be controlled (OGTR, 2013). This is determined by legislation, government policies, national and international guidance material, and widely acceptable community norms. Undesirable plants that cause economic, social or environmental harm, or harm to human/animal health, are called weeds. Animals that cause harm are known as pests. [↑](#footnote-ref-3)
3. As none of the proposed dealings are considered to pose a significant risk to people or the environment, Section 52(2)(d)(ii) of the Act mandates a minimum period of 30 days for consultation on the RARMP. [↑](#footnote-ref-4)
4. Prescribed experts, agencies and authorities include the Gene Technology Technical Advisory Committee, State and Territory Governments, relevant local governments, Australian government agencies and the Minister for the Environment. [↑](#footnote-ref-5)